

BioMed Realty Trust Inc
Form 10-Q
November 05, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

QUARTERLY REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

Commission File Number: 1-32261 (BioMed Realty Trust, Inc.)
000-54089 (BioMed Realty, L.P.)
BIOMED REALTY TRUST, INC.
BIOMED REALTY, L.P.
(Exact name of registrant as specified in its charter)

Maryland
(State or other jurisdiction of
incorporation or organization)

20-1142292 (BioMed Realty Trust, Inc.)
20-1320636 (BioMed Realty, L.P.)
(I.R.S. Employer Identification No.)

17190 Bernardo Center Drive
San Diego, California
(Address of Principal Executive Offices)
(858) 485-9840

92128
(Zip Code)

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

BioMed Realty Trust, Inc. Yes No

BioMed Realty, L.P. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

BioMed Realty Trust, Inc. Yes No

BioMed Realty, L.P. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

BioMed Realty Trust, Inc.:

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company
(Do not check if a smaller reporting company)

BioMed Realty, L.P.:

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

BioMed Realty Trust, Inc. Yes No

BioMed Realty, L.P. Yes No

The number of outstanding shares of BioMed Realty Trust, Inc.'s common stock, par value \$0.01 per share, as of November 5, 2015 was 203,527,787.

Table of Contents

EXPLANATORY NOTE

This report combines the quarterly reports on Form 10-Q for the quarter ended September 30, 2015 of BioMed Realty Trust, Inc., a Maryland corporation, and BioMed Realty, L.P., a Maryland limited partnership of which BioMed Realty Trust, Inc. is the parent company and general partner. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “we,” “us,” “our” or “our company” refer to BioMed Realty Trust, Inc. together with its consolidated subsidiaries, including BioMed Realty, L.P. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “our operating partnership” or “the operating partnership” refer to BioMed Realty, L.P. together with its consolidated subsidiaries.

BioMed Realty Trust, Inc. operates as a real estate investment trust, or REIT, and is the general partner of BioMed Realty, L.P. As of September 30, 2015, BioMed Realty Trust, Inc. owned an approximate 97.5% partnership interest and other limited partners, including some of our directors, executive officers and their affiliates, owned the remaining 2.5% partnership interest (including long term incentive plan units) in BioMed Realty, L.P. As the sole general partner of BioMed Realty, L.P., BioMed Realty Trust, Inc. has the full, exclusive and complete responsibility for the operating partnership’s day-to-day management and control.

There are a few differences between our company and our operating partnership, which are reflected in the disclosure in this report. We believe it is important to understand the differences between our company and our operating partnership in the context of how BioMed Realty Trust, Inc. and BioMed Realty, L.P. operate as an interrelated consolidated company. BioMed Realty Trust, Inc. is a REIT, whose only material asset is its ownership of partnership interests of the operating partnership. As a result, BioMed Realty Trust, Inc. does not conduct business itself, other than acting as the sole general partner of BioMed Realty, L.P., issuing public equity from time to time and guaranteeing certain debt of BioMed Realty, L.P. BioMed Realty Trust, Inc. itself does not hold any indebtedness but guarantees some of the secured and unsecured debt of BioMed Realty, L.P. BioMed Realty, L.P. holds substantially all the assets of the company and holds the ownership interests in the company’s joint ventures. BioMed Realty, L.P. conducts the operations of the business and is structured as a partnership with no publicly-traded equity. Except for net proceeds from public equity issuances by BioMed Realty Trust, Inc., which are generally contributed to BioMed Realty, L.P. in exchange for partnership units, BioMed Realty, L.P. generates the capital required by the company’s business through BioMed Realty, L.P.’s operations, by BioMed Realty, L.P.’s direct or indirect incurrence of indebtedness or through the issuance of partnership units.

Noncontrolling interests and stockholders’ equity and partners’ capital are the main areas of difference between the consolidated financial statements of BioMed Realty Trust, Inc. and those of BioMed Realty, L.P. The operating partnership and long term incentive plan units in BioMed Realty, L.P. that are not owned by BioMed Realty Trust, Inc. are accounted for as partners’ capital in BioMed Realty, L.P.’s financial statements and as noncontrolling interests in BioMed Realty Trust, Inc.’s financial statements. The noncontrolling interests in BioMed Realty, L.P.’s financial statements include the interests of joint venture partners. The noncontrolling interests in BioMed Realty Trust, Inc.’s financial statements include the same noncontrolling interests at the BioMed Realty, L.P. level as well as the limited partnership unit holders of BioMed Realty, L.P., not including BioMed Realty Trust, Inc. The differences between stockholders’ equity and partners’ capital result from the differences in the equity issued at the BioMed Realty Trust, Inc. and BioMed Realty, L.P. levels.

We believe combining the quarterly reports on Form 10-Q of BioMed Realty Trust, Inc. and BioMed Realty, L.P. into this single report:

- better reflects how management and the analyst community view the business as a single operating unit,
 - enhances investor understanding of our company by enabling them to view the business as a whole and in the same manner as management,
 - is more efficient for our company and results in savings in time, effort and expense, and
 - is more efficient for investors by reducing duplicative disclosure and providing a single document for their review.
- To help investors understand the significant differences between our company and our operating partnership, this report presents the following separate sections for each of BioMed Realty Trust, Inc. and BioMed Realty, L.P.:
- consolidated financial statements,
 - the following notes to the consolidated financial statements:

Equity / Partners' Capital,
Debt, and

2

Table of Contents

Earnings Per Share / Unit,

Liquidity and Capital Resources in Management's Discussion and Analysis of Financial Condition and Results of Operations, and

Unregistered Sales of Equity Securities and Use of Proceeds.

This report also includes separate Item 4. Controls and Procedures sections and separate Exhibit 31 and 32 certifications for each of BioMed Realty Trust, Inc. and BioMed Realty, L.P. in order to establish that the Chief Executive Officer and the Chief Financial Officer of BioMed Realty Trust, Inc. have made the requisite certifications and BioMed Realty Trust, Inc. and BioMed Realty, L.P. are compliant with Rule 13a-15 or Rule 15d-15 of the Securities Exchange Act of 1934 and 18 U.S.C. §1350.

BIOMED REALTY TRUST, INC. AND BIOMED REALTY, L.P.

FORM 10-Q - QUARTERLY REPORT
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2015
TABLE OF CONTENTS

| | Page |
|--|-----------|
| <u>PART I - FINANCIAL INFORMATION</u> | |
| <u>Item 1 Consolidated Financial Statements</u> | <u>6</u> |
| <u>Consolidated Financial Statements of BioMed Realty Trust, Inc.:</u> | <u>7</u> |
| <u>Consolidated Balance Sheets as of September 30, 2015 (Unaudited) and December 31, 2014</u> | <u>7</u> |
| <u>Consolidated Statements of Income for the three and nine months ended September 30, 2015 and 2014 (Unaudited)</u> | <u>8</u> |
| <u>Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2015 and 2014 (Unaudited)</u> | <u>9</u> |
| <u>Consolidated Statement of Equity for the nine months ended September 30, 2015 (Unaudited)</u> | <u>10</u> |
| <u>Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014 (Unaudited)</u> | <u>11</u> |
| <u>Consolidated Financial Statements of BioMed Realty, L.P.:</u> | <u>13</u> |
| <u>Consolidated Balance Sheets as of September 30, 2015 (Unaudited) and December 31, 2014</u> | <u>13</u> |
| <u>Consolidated Statements of Income for the three and nine months ended September 30, 2015 and 2014 (Unaudited)</u> | <u>14</u> |
| <u>Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2015 and 2014 (Unaudited)</u> | <u>15</u> |
| <u>Consolidated Statement of Capital for the nine months ended September 30, 2015 (Unaudited)</u> | <u>16</u> |
| <u>Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014 (Unaudited)</u> | <u>17</u> |
| <u>Notes to Consolidated Financial Statements of BioMed Realty Trust, Inc. and BioMed Realty, L.P.</u> | <u>19</u> |
| <u>Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | <u>36</u> |
| <u>Item 3 Quantitative and Qualitative Disclosures About Market Risk</u> | <u>55</u> |
| <u>Item 4 Controls and Procedures</u> | <u>58</u> |
| <u>PART II - OTHER INFORMATION</u> | |

| | |
|---------------------------------|-----------|
| <u>Item 1 Legal Proceedings</u> | <u>59</u> |
|---------------------------------|-----------|

| | |
|-----------------------------|-----------|
| <u>Item 1A Risk Factors</u> | <u>59</u> |
|-----------------------------|-----------|

| | |
|--|-----------|
| <u>Item 2 Unregistered Sale of Equity Securities and Use of Proceeds</u> | <u>60</u> |
| <u>Item 3 Defaults Upon Senior Securities</u> | <u>61</u> |
| <u>Item 4 Mine Safety Disclosures</u> | <u>61</u> |
| <u>Item 5 Other Information</u> | <u>61</u> |
| <u>Item 6 Exhibits</u> | <u>62</u> |
| <u>SIGNATURES</u> | <u>63</u> |
| Exhibit 31.1 | |
| Exhibit 31.2 | |
| Exhibit 32.1 | |

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

6

Table of Contents

BIOMED REALTY TRUST, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

| | September 30, 2015 (Unaudited) | December 31, 2014 |
|---|--------------------------------------|----------------------|
| ASSETS | | |
| Land | \$667,391 | \$704,958 |
| Building and improvements | 5,252,993 | 4,877,135 |
| Land under development | 243,623 | 151,242 |
| Construction in progress | 638,078 | 629,679 |
| Investments in real estate | 6,802,085 | 6,363,014 |
| Accumulated depreciation | (1,080,838 |) (946,439 |
| Investments in real estate, net | 5,721,247 | 5,416,575 |
| Investments in unconsolidated partnerships | 29,367 | 35,291 |
| Cash and cash equivalents | 48,675 | 46,659 |
| Accounts receivable, net | 19,139 | 14,631 |
| Accrued straight-line rents, net | 177,423 | 163,716 |
| Deferred leasing costs, net | 226,956 | 219,713 |
| Other assets | 237,889 | 274,301 |
| Total assets | \$6,460,696 | \$6,170,886 |
| LIABILITIES AND EQUITY | | |
| Mortgage notes payable, net | \$492,065 | \$496,757 |
| Exchangeable senior notes | — | 95,678 |
| Unsecured senior notes, net | 1,294,978 | 1,293,903 |
| Unsecured senior term loans | 745,126 | 749,326 |
| Unsecured line of credit | 463,000 | 84,000 |
| Accounts payable, accrued expenses and other liabilities | 419,418 | 381,280 |
| Total liabilities | 3,414,587 | 3,100,944 |
| Equity: | | |
| Stockholders' equity: | | |
| Common stock, \$.01 par value, 300,000,000 shares and 250,000,000 shares authorized, and 203,527,787 shares and 197,442,432 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively | 2,036 | 1,975 |
| Additional paid-in capital | 3,754,137 | 3,649,235 |
| Accumulated other comprehensive loss, net | (39,725 |) (2,214 |
| Dividends in excess of earnings | (735,627 |) (645,983 |
| Total stockholders' equity | 2,980,821 | 3,003,013 |
| Noncontrolling interests | 65,288 | 66,929 |
| Total equity | 3,046,109 | 3,069,942 |
| Total liabilities and equity | \$6,460,696 | \$6,170,886 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except share data)

(Unaudited)

| | For the Three Months Ended September 30, | | For the Nine Months Ended September 30, | |
|---|---|-------------|--|-------------|
| | 2015 | 2014 | 2015 | 2014 |
| Revenues: | | | | |
| Rental | \$123,332 | \$122,838 | \$357,112 | \$363,788 |
| Tenant recoveries | 47,539 | 42,626 | 133,068 | 121,641 |
| Other revenue | 3,477 | 3,452 | 20,152 | 23,524 |
| Total revenues | 174,348 | 168,916 | 510,332 | 508,953 |
| Expenses: | | | | |
| Rental operations | 62,069 | 54,899 | 175,986 | 161,058 |
| Depreciation and amortization | 64,953 | 64,452 | 193,305 | 189,597 |
| General and administrative | 13,166 | 12,768 | 38,486 | 37,153 |
| Executive severance | — | — | 9,891 | — |
| Acquisition-related expenses | 720 | 487 | 2,284 | 2,871 |
| Total expenses | 140,908 | 132,606 | 419,952 | 390,679 |
| Income from operations | 33,440 | 36,310 | 90,380 | 118,274 |
| Equity in net income of unconsolidated partnerships | 242 | 733 | 534 | 585 |
| Interest expense, net | (21,228) |) (22,215) |) (61,938) |) (73,356) |
| Gain on sale of real estate | 1,869 | — | 1,869 | — |
| Impairment of real estate | — | — | (35,071) |) — |
| Other income, net | 18,770 | 2,148 | 95,675 | 11,338 |
| Net income | 33,093 | 16,976 | 91,449 | 56,841 |
| Net income attributable to noncontrolling interests | (4,890) |) (1,016) |) (22,323) |) (3,412) |
| Net income attributable to the Company | 28,203 | 15,960 | 69,126 | 53,429 |
| Net income per share attributable to common stockholders: | | | | |
| Basic and diluted earnings per share | \$0.14 | \$0.08 | \$0.34 | \$0.27 |
| Weighted-average common shares outstanding: | | | | |
| Basic | 202,210,976 | 194,022,619 | 201,746,167 | 191,988,661 |
| Diluted | 207,801,584 | 199,574,893 | 207,325,554 | 197,651,357 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

(Unaudited)

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------|----------|-------------------|----------|
| | September 30, | | September 30, | |
| | 2015 | 2014 | 2015 | 2014 |
| Net income | \$33,093 | \$16,976 | \$91,449 | \$56,841 |
| Other comprehensive income: | | | | |
| Foreign currency translation adjustments | (1,737) | (1,472) | (1,473) | (484) |
| Unrealized (loss) / gain on derivative instruments, net | (1,026) | 169 | (1,984) | (749) |
| Amortization of deferred interest costs | 1,647 | 1,677 | 4,965 | 5,052 |
| Reclassification on sale of equity securities | (17,944) | — | (85,767) | (9,322) |
| Unrealized gain on equity securities | 541 | 3,550 | 37,879 | 20,300 |
| Total other comprehensive (loss) / income | (18,519) | 3,924 | (46,380) | 14,797 |
| Comprehensive income | 14,574 | 20,900 | 45,069 | 71,638 |
| Comprehensive income attributable to noncontrolling interests | (1,552) | (1,767) | (13,454) | (6,201) |
| Comprehensive income attributable to the Company | \$13,022 | \$19,133 | \$31,615 | \$65,437 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENT OF EQUITY

(In thousands, except share data)

(Unaudited)

| | Common Stock Shares | Common Stock Amount | Additional Paid-In Capital | Accumulated Other Comprehensive Loss, net | Dividends in Excess of Earnings | Total Stockholders' Equity | Noncontrolling Interests | Total Equity |
|--|------------------------|------------------------|----------------------------------|--|---------------------------------------|----------------------------------|-----------------------------|--------------|
| Balance at December 31, 2014 | 197,442,432 | \$ 1,975 | \$ 3,649,235 | \$ (2,214) | \$ (645,983) | \$ 3,003,013 | \$ 66,929 | \$ 3,069,942 |
| Net issuances of unvested restricted common stock | 314,079 | 4 | (5,770) | — | — | (5,766) | — | (5,766) |
| Exchange of Exchangeable Senior Notes | 5,764,026 | 57 | 95,699 | — | — | 95,756 | — | 95,756 |
| Conversion of OP units to common stock | 7,250 | — | (40) | — | — | (40) | 40 | — |
| Vesting of share-based awards | — | — | 14,805 | — | — | 14,805 | — | 14,805 |
| Reallocation of noncontrolling interests to equity | — | — | 1,567 | — | — | 1,567 | (1,567) | — |
| Common stock dividends | — | — | — | — | (158,770) | (158,770) | — | (158,770) |
| OP unit distributions | — | — | — | — | — | — | (4,213) | (4,213) |
| Purchases of noncontrolling interests | — | — | (1,359) | — | — | (1,359) | 859 | (500) |
| Contributions from noncontrolling interests | — | — | — | — | — | — | 4,450 | 4,450 |
| Distributions to noncontrolling interests | — | — | — | — | — | — | (14,664) | (14,664) |
| Net income | — | — | — | — | 69,126 | 69,126 | 22,323 | 91,449 |
| Foreign currency translation adjustments | — | — | — | (1,436) | — | (1,436) | (37) | (1,473) |
| Reclassification on sale of equity securities | — | — | — | (68,642) | — | (68,642) | (17,125) | (85,767) |
| Unrealized gain on equity securities | — | — | — | 29,662 | — | 29,662 | 8,217 | 37,879 |

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

| | | | | | | | | |
|--|-------------|---------|-------------|-------------|-------------|-------------|-----------|-------------|
| Amortization of deferred interest costs | — | — | — | 4,838 | — | 4,838 | 127 | 4,965 |
| Unrealized loss on derivative instruments, net | — | — | — | (1,933) | — | (1,933) | (51) | (1,984) |
| Balance at September 30, 2015 | 203,527,787 | \$2,036 | \$3,754,137 | \$(39,725) | \$(735,627) | \$2,980,821 | \$ 65,288 | \$3,046,109 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

| | Nine Months Ended September 30, | |
|---|------------------------------------|------------|
| | 2015 | 2014 |
| Operating activities: | | |
| Net income | \$91,449 | \$56,841 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 193,305 | 189,597 |
| Allowance for doubtful accounts | 1,870 | 526 |
| Impairment of real estate | 35,071 | — |
| Gain on sale of debt and equity securities | (85,767) | — |
| Gain on repayment of notes receivable | (8,557) | — |
| Gain on sale of real estate | (1,869) | — |
| Non-cash revenue adjustments | 1,270 | 942 |
| Other non-cash adjustments | 10,000 | 5,146 |
| Compensation expense related to share based payments | 14,805 | 11,137 |
| Distributions representing a return on capital from unconsolidated partnerships | 1,893 | 399 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (4,718) | (10,607) |
| Accrued straight-line rents | (15,384) | (10,466) |
| Deferred leasing costs | (30,613) | (10,526) |
| Other assets | (9,137) | (24,478) |
| Accounts payable, accrued expenses and other liabilities | 12,925 | 15,355 |
| Net cash provided by operating activities | 206,543 | 223,866 |
| Investing activities: | | |
| Purchases of investments in real estate and related intangible assets | (210,509) | (130,458) |
| Capital expenditures | (307,161) | (300,716) |
| Contributions from tax credit transactions, net | 11,938 | 22,557 |
| Proceeds from sale of property, net of selling costs | 41,398 | — |
| Draws on notes and construction loan receivable | (10,817) | (39,769) |
| Repayment of notes receivable | 11,418 | 184,239 |
| Distributions from / (contributions to) unconsolidated partnerships, net | 3,571 | (4,760) |
| Purchases of debt and equity securities | (33,776) | (15,725) |
| Proceeds from the sale of debt and equity securities | 90,378 | 13,952 |
| Net cash used in investing activities | (403,560) | (270,680) |
| Financing activities: | | |
| Payment of deferred loan costs | (78) | (3,101) |
| Unsecured line of credit proceeds | 407,000 | 732,000 |
| Unsecured line of credit payments | (28,000) | (631,000) |
| Mortgage notes proceeds | 25,559 | 39,237 |
| Principal payments on mortgage notes payable | (28,564) | (340,124) |
| Proceeds from unsecured senior notes | — | 397,632 |
| Distributions to noncontrolling interests | (14,664) | — |
| Purchases of noncontrolling interests | (500) | — |

Distributions to operating partnership unit and LTIP unit holders

(4,214) (4,175)

11

Table of Contents

| | Nine Months Ended September 30, | |
|---|------------------------------------|------------|
| | 2015 | 2014 |
| Dividends paid to common stockholders | (157,189) | (144,289) |
| Net cash provided by financing activities | 199,350 | 46,180 |
| Effect of exchange rate changes on cash and cash equivalents | (317) | (208) |
| Net increase / (decrease) in cash and cash equivalents | 2,016 | (842) |
| Cash and cash equivalents at beginning of period | 46,659 | 34,706 |
| Cash and cash equivalents at end of period | \$48,675 | \$33,864 |
| Supplemental disclosure of cash flow information: | | |
| Cash paid during the period for interest (net of amounts capitalized of \$21,657 and \$15,734, for the nine months ended September 30, 2015 and 2014, respectively) | \$45,555 | \$59,233 |
| Supplemental disclosure of non-cash investing and financing activities: | | |
| Accrual for common stock dividends declared | \$52,916 | \$49,363 |
| Accrual for distributions declared for operating partnership unit and LTIP unit holders | 1,404 | 1,351 |
| Accrued additions to real estate and related intangible assets | 117,032 | 113,704 |
| Mortgage notes assumed (includes premium of \$3,966 during the nine months ended September 30, 2014) | — | 71,937 |
| Exchange of Exchangeable Senior Notes for common stock | 95,678 | 84,322 |
| Noncontrolling interests in connection with South Street Landing, 100 College Street and 300 George Street acquisitions | 3,000 | 21,740 |
| Notes receivable applied for investments in real estate | 7,505 | — |
| Deposits applied for investments in real estate | 17,882 | — |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY, L.P.

CONSOLIDATED BALANCE SHEETS

(In thousands, except unit data)

| | September 30, 2015 (Unaudited) | December 31, 2014 |
|---|--------------------------------------|----------------------|
| ASSETS | | |
| Land | \$667,391 | \$704,958 |
| Building and improvements | 5,252,993 | 4,877,135 |
| Land under development | 243,623 | 151,242 |
| Construction in progress | 638,078 | 629,679 |
| Investments in real estate | 6,802,085 | 6,363,014 |
| Accumulated depreciation | (1,080,838 |) (946,439 |
| Investments in real estate, net | 5,721,247 | 5,416,575 |
| Investments in unconsolidated partnerships | 29,367 | 35,291 |
| Cash and cash equivalents | 48,675 | 46,659 |
| Accounts receivable, net | 19,139 | 14,631 |
| Accrued straight-line rents, net | 177,423 | 163,716 |
| Deferred leasing costs, net | 226,956 | 219,713 |
| Other assets | 237,889 | 274,301 |
| Total assets | \$6,460,696 | \$6,170,886 |
| LIABILITIES AND CAPITAL | | |
| Mortgage notes payable, net | \$492,065 | \$496,757 |
| Exchangeable senior notes | — | 95,678 |
| Unsecured senior notes, net | 1,294,978 | 1,293,903 |
| Unsecured senior term loans | 745,126 | 749,326 |
| Unsecured line of credit | 463,000 | 84,000 |
| Accounts payable, accrued expenses and other liabilities | 419,418 | 381,280 |
| Total liabilities | 3,414,587 | 3,100,944 |
| Capital: | | |
| Partners' capital: | | |
| Limited partners' capital, 5,398,224 and 5,405,474 units issued and outstanding at September 30, 2015 and December 31, 2014, respectively | 42,484 | 45,600 |
| General partner's capital, 203,527,787 and 197,442,432 units issued and outstanding at September 30, 2015 and December 31, 2014, respectively | 3,016,634 | 3,002,135 |
| Accumulated other comprehensive (loss) / income | (35,813 |) 878 |
| Total partners' capital | 3,023,305 | 3,048,613 |
| Noncontrolling interests | 22,804 | 21,329 |
| Total capital | 3,046,109 | 3,069,942 |
| Total liabilities and capital | \$6,460,696 | \$6,170,886 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY, L.P.

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except unit data)

(Unaudited)

| | For the Three Months Ended September 30, | | For the Nine Months Ended September 30, | |
|--|---|-------------|--|-------------|
| | 2015 | 2014 | 2015 | 2014 |
| Revenues: | | | | |
| Rental | \$ 123,332 | \$ 122,838 | \$ 357,112 | \$ 363,788 |
| Tenant recoveries | 47,539 | 42,626 | 133,068 | 121,641 |
| Other revenue | 3,477 | 3,452 | 20,152 | 23,524 |
| Total revenues | 174,348 | 168,916 | 510,332 | 508,953 |
| Expenses: | | | | |
| Rental operations | 62,069 | 54,899 | 175,986 | 161,058 |
| Depreciation and amortization | 64,953 | 64,452 | 193,305 | 189,597 |
| General and administrative | 13,166 | 12,768 | 38,486 | 37,153 |
| Executive severance | — | — | 9,891 | — |
| Acquisition-related expenses | 720 | 487 | 2,284 | 2,871 |
| Total expenses | 140,908 | 132,606 | 419,952 | 390,679 |
| Income from operations | 33,440 | 36,310 | 90,380 | 118,274 |
| Equity in net income of unconsolidated partnerships | 242 | 733 | 534 | 585 |
| Interest expense, net | (21,228) |) (22,215) |) (61,938) |) (73,356) |
| Gain on sale of real estate | 1,869 | — | 1,869 | — |
| Impairment of real estate | — | — | (35,071) |) — |
| Other income, net | 18,770 | 2,148 | 95,675 | 11,338 |
| Net income | 33,093 | 16,976 | 91,449 | 56,841 |
| Net income attributable to noncontrolling interests | (4,156) |) (587) |) (20,519) |) (1,948) |
| Net income attributable to the Operating Partnership | 28,937 | 16,389 | 70,930 | 54,893 |
| Net income per unit attributable to unit holders: | | | | |
| Basic and diluted earnings per unit | \$0.14 | \$0.08 | \$0.34 | \$0.27 |
| Weighted-average units outstanding: | | | | |
| Basic | 207,609,199 | 199,428,093 | 207,147,153 | 197,395,750 |
| Diluted | 207,801,583 | 199,574,893 | 207,325,554 | 197,651,357 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY, L.P.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

(Unaudited)

| | Three Months Ended | | Nine Months Ended | |
|--|--------------------|----------|-------------------|----------|
| | September 30, | | September 30, | |
| | 2015 | 2014 | 2015 | 2014 |
| Net income | \$33,093 | \$16,976 | \$91,449 | \$56,841 |
| Other comprehensive income: | | | | |
| Foreign currency translation adjustments | (1,737) | (1,472) | (1,473) | (484) |
| Unrealized (loss) / gain on derivative instruments, net | (1,026) | 169 | (1,984) | (749) |
| Amortization of deferred interest costs | 1,647 | 1,677 | 4,965 | 5,052 |
| Reclassification on sale of equity securities | (17,944) | — | (85,767) | (9,322) |
| Unrealized gain on equity securities | 541 | 3,550 | 37,879 | 20,300 |
| Total other comprehensive (loss) / income | (18,519) | 3,924 | (46,380) | 14,797 |
| Comprehensive income | 14,574 | 20,900 | 45,069 | 71,638 |
| Comprehensive income attributable to noncontrolling interests | (839) | (1,253) | (10,830) | (4,409) |
| Comprehensive income attributable to the Operating Partnership | \$13,735 | \$19,647 | \$34,239 | \$67,229 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY, L.P.

CONSOLIDATED STATEMENT OF CAPITAL

(In thousands, except unit data)

(Unaudited)

| | Limited Partners' Capital | | General Partner's Capital | | Accumulated Other Comprehensive Income / (Loss) | Total Partners' Capital | Noncontrolling Interests | Total Capital |
|---|---------------------------|----------|---------------------------|-------------|---|-------------------------|--------------------------|---------------|
| | Units | Amount | Units | Amount | | | | |
| Balance at December 31, 2014 | 5,405,474 | \$45,600 | 197,442,432 | \$3,002,135 | \$ 878 | \$3,048,613 | \$ 21,329 | \$3,069,942 |
| Net issuances of unvested restricted OP units | — | — | 314,079 | (5,766) | — | (5,766) | — | (5,766) |
| Conversion of OP units | (7,250) | 40 | 7,250 | (40) | — | — | — | — |
| Exchange of Exchangeable Senior Notes | — | — | 5,764,026 | 95,756 | — | 95,756 | — | 95,756 |
| Vesting of share-based awards | — | — | — | 14,805 | — | 14,805 | — | 14,805 |
| Reallocation of capital | — | (747) | — | 747 | — | — | — | — |
| Distributions | — | (4,213) | — | (158,770) | — | (162,983) | — | (162,983) |
| Purchases of noncontrolling interests | — | — | — | (1,359) | — | (1,359) | 859 | (500) |
| Contributions from noncontrolling interests | — | — | — | — | — | — | 4,450 | 4,450 |
| Distributions to noncontrolling interests | — | — | — | — | — | — | (14,664) | (14,664) |
| Net income | — | 1,804 | — | 69,126 | — | 70,930 | 20,519 | 91,449 |
| Foreign currency translation adjustments | — | — | — | — | (1,473) | (1,473) | — | (1,473) |
| Reclassification on sale of equity securities | — | — | — | — | (68,642) | (68,642) | (17,125) | (85,767) |
| Unrealized gain on equity securities | — | — | — | — | 30,443 | 30,443 | 7,436 | 37,879 |

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

| | | | | | | | | |
|--|-----------|----------|-------------|-------------|-------------|-------------|-----------|-------------|
| Amortization of deferred interest costs | — | — | — | — | 4,965 | 4,965 | — | 4,965 |
| Unrealized loss on derivative instruments, net | — | — | — | — | (1,984) | (1,984) | — | (1,984) |
| Balance at September 30, 2015 | 5,398,224 | \$42,484 | 203,527,787 | \$3,016,634 | \$(35,813) | \$3,023,305 | \$ 22,804 | \$3,046,109 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY, L.P.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

| | Nine Months Ended September 30, | |
|---|------------------------------------|--------------|
| | 2015 | 2014 |
| Operating activities: | | |
| Net income | \$91,449 | \$56,841 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 193,305 | 189,597 |
| Allowance for doubtful accounts | 1,870 | 526 |
| Impairment of real estate | 35,071 | — |
| Gain on sale of debt and equity securities | (85,767) |) |
| Gain on repayment of notes receivable | (8,557) |) |
| Gain on sale of real estate | (1,869) |) |
| Non-cash revenue adjustments | 1,270 | 942 |
| Other non-cash adjustments | 10,000 | 5,146 |
| Compensation expense related to share-based payments | 14,805 | 11,137 |
| Distributions representing a return on capital from unconsolidated partnerships | 1,893 | 399 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (4,718) |) (10,607) |
| Accrued straight-line rents | (15,384) |) (10,466) |
| Deferred leasing costs | (30,613) |) (10,526) |
| Other assets | (9,137) |) (24,478) |
| Accounts payable, accrued expenses and other liabilities | 12,925 | 15,355 |
| Net cash provided by operating activities | 206,543 | 223,866 |
| Investing activities: | | |
| Purchases of investments in real estate and related intangible assets | (210,509) |) (130,458) |
| Capital expenditures | (307,161) |) (300,716) |
| Contributions from tax credit transactions, net | 11,938 | 22,557 |
| Proceeds from sale of properties, net of selling costs | 41,398 | — |
| Draws on notes and construction loan receivable | (10,817) |) (39,769) |
| Repayment of notes receivable | 11,418 | 184,239 |
| Distributions from / (contributions to) unconsolidated partnerships, net | 3,571 | (4,760) |
| Purchases of debt and equity securities | (33,776) |) (15,725) |
| Proceeds from the sale of debt and equity securities | 90,378 | 13,952 |
| Net cash used in investing activities | (403,560) |) (270,680) |
| Financing activities: | | |
| Payment of deferred loan costs | (78) |) (3,101) |
| Unsecured line of credit proceeds | 407,000 | 732,000 |
| Unsecured line of credit payments | (28,000) |) (631,000) |
| Mortgage notes proceeds | 25,559 | 39,237 |
| Principal payments on mortgage notes payable | (28,564) |) (340,124) |
| Proceeds from unsecured senior notes | — | 397,632 |

Table of Contents

| | Nine Months Ended September 30, | |
|---|------------------------------------|--------------|
| | 2015 | 2014 |
| Purchases of interests in noncontrolling interest | (500 |) — |
| Distributions to noncontrolling interests | (14,664 |) — |
| Distributions paid to unit holders | (161,403 |) (148,464) |
| Net cash provided by financing activities | 199,350 | 46,180 |
| Effect of exchange rate changes on cash and cash equivalents | (317 |) (208) |
| Net increase / (decrease) in cash and cash equivalents | 2,016 | (842) |
| Cash and cash equivalents at beginning of period | 46,659 | 34,706 |
| Cash and cash equivalents at end of period | \$48,675 | \$33,864 |
| Supplemental disclosure of cash flow information: | | |
| Cash paid during the period for interest (net of amounts capitalized of \$21,657 and \$15,734, for the nine months ended September 30, 2015 and 2014, respectively) | \$45,555 | \$59,233 |
| Supplemental disclosure of non-cash investing and financing activities: | | |
| Accrual for unit distributions declared | \$54,320 | \$50,714 |
| Accrued additions to real estate and related intangible assets | 117,032 | 113,704 |
| Mortgage notes assumed (includes premiums of \$3,966 during the nine months ended September 30, 2014) | — | 71,937 |
| Noncontrolling interests in connection with South Street Landing, 100 College Street and 300 George Street acquisitions | 3,000 | 21,740 |
| Exchange of Exchangeable Senior Notes for common units | 95,678 | 84,322 |
| Notes receivable applied for investments in real estate | 7,505 | — |
| Deposits applied for investments in real estate | 17,882 | — |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY TRUST, INC.

BIOMED REALTY, L.P.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization of the Parent Company and Description of Business

BioMed Realty Trust, Inc., a Maryland corporation (the “Parent Company”), operates as a fully integrated, self-administered and self-managed real estate investment trust (“REIT”) focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry principally through its subsidiary, BioMed Realty, L.P., a Maryland limited partnership (the “Operating Partnership” and together with the Parent Company referred to as the “Company”). The Company’s tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company’s properties are generally located in markets with well-established reputations as centers for scientific research, including Boston, San Francisco, San Diego, Maryland, New York / New Jersey, Pennsylvania, North Carolina, Seattle, Cambridge (United Kingdom) and research parks located near or adjacent to universities and their related medical systems.

The Parent Company is the sole general partner of the Operating Partnership and, as of September 30, 2015, owned a 97.5% interest in the Operating Partnership. The remaining 2.5% interest in the Operating Partnership is held by limited partners. Each partner’s percentage interest in the Operating Partnership is determined based on the number of operating partnership units and long-term incentive plan units (“LTIP units” and together with the operating partnership units, the “OP units”) owned as compared to total OP units (and potentially issuable OP units, as applicable) outstanding as of each period end and is used as the basis for the allocation of net income or loss to each partner.

2. Basis of Presentation and Summary of Significant Accounting Policies

The accompanying interim financial statements are unaudited, but have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in conjunction with the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, they do not include all the disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments and eliminations, consisting of normal recurring adjustments necessary for a fair presentation of the financial statements for these interim periods have been recorded. These financial statements should be read in conjunction with the audited consolidated financial statements and notes therein included in the Company’s annual report on Form 10-K for the year ended December 31, 2014.

Reclassifications

Certain reclassifications have been made to prior period amounts to conform to current period presentation. Such reclassifications have no effect on net income as previously reported.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, partnerships and limited liability companies that it controls, and variable interest entities (“VIEs”) for which the Company has determined itself to be the primary beneficiary. All material intercompany transactions and balances have been eliminated. The Company consolidates entities the Company controls and records a noncontrolling interest for the portions not owned by the Company. Control is determined, where applicable, by the sufficiency of equity

invested and the rights of the equity holders, and by the ownership of a majority of the voting interests, with consideration given to the existence of approval or veto rights granted to the minority stockholder. If the minority stockholder holds substantive participating rights, it overcomes the presumption of control by the majority voting interest holder. In contrast, if the minority stockholder simply holds protective rights (such as consent rights over certain actions), it does not overcome the presumption of control by the majority voting interest holder.

Assets and liabilities of subsidiaries outside the United States with non-U.S. dollar functional currencies are translated into U.S. dollars using exchange rates as of the balance sheet dates. Income and expenses are translated using the average exchange rates for the reporting period. Foreign currency translation adjustments are recorded as a component of other comprehensive income. For the three months ended September 30, 2015 and 2014, total revenues from properties outside the United States were \$4.5 million and \$6.5 million, respectively, which represented 2.6% and 3.8% of the Company's total revenues during the respective periods. For the nine months ended September 30, 2015 and 2014, total revenues from properties outside the United States were \$13.1 million and \$16.1 million, respectively, which represented 2.6% and 3.2% of the Company's total revenues during the

Table of Contents

respective periods. The Company's net investments in properties outside the United States were \$211.3 million and \$200.2 million at September 30, 2015 and December 31, 2014, respectively.

Investments in Partnerships and Limited Liability Companies

The Company has determined that it is the primary beneficiary in six VIEs (excluding certain VIEs associated with tax credits discussed below), consisting of single-tenant properties in which the tenant has a purchase option, which are consolidated and reflected in the accompanying consolidated financial statements. Selected financial data of the VIEs at September 30, 2015 and December 31, 2014 consist of the following (in thousands):

| | September 30, 2015 | December 31, 2014 |
|--------------------------------|-----------------------|----------------------|
| Investment in real estate, net | \$435,945 | \$433,842 |
| Total assets | 504,025 | 493,066 |
| Total debt | 186,694 | 189,848 |
| Total liabilities | 200,211 | 203,529 |

Historic Tax Credits and New Market Tax Credits

The Company is a party to certain contractual arrangements with tax credit investors ("TCIs") that were established to enable the TCIs to receive benefits of historic tax credits ("HTCs") and/or new market tax credits ("NMTCs") for certain properties owned by the Company. At September 30, 2015 and December 31, 2014, the Company owned eleven and ten properties, respectively, that had syndicated HTCs or NMTCs, or both, to TCIs.

Capital contributions are made by TCIs into special purpose entities that ultimately invest these funds in the entity that owns the subject property that generates the tax credits. The TCIs are allocated substantially all of the tax credits and hold only a noncontrolling interest in the economic risk and rewards of the special purpose entities. HTCs are delivered to the TCI upon substantial completion of the project. NMTCs are allowed for up to 39% of a qualified investment and are delivered to the TCI after the investment has been funded and spent on a qualified business. HTCs are subject to 20% recapture per year beginning one year after the completion of the historic rehabilitation of the subject property. NMTCs are subject to 100% recapture until the end of the seventh year following the qualifying investment. The Company has provided the TCIs with certain guarantees which protect the TCIs from loss should a tax credit recapture event occur. The contractual arrangements with the TCIs include a put/call provision whereby the Company may be obligated or entitled to repurchase the ownership interest of the TCIs in the special purpose entities at the end of the tax credit recapture period. The Company anticipates that either the TCIs will exercise their put rights or the Company will exercise its call rights; however, the Company believes that the put rights are more likely to be exercised.

The portion of the TCI's capital contribution that is attributed to the put is recorded at fair-value at inception and is accreted to the expected put price as interest expense in the consolidated statements of income. At September 30, 2015 and December 31, 2014, approximately \$5.6 million and \$5.2 million of put liabilities, respectively, were included in other liabilities in the consolidated balance sheets. The remaining balance of the TCI's capital contribution is initially recorded in other liabilities in the consolidated balance sheets and is reclassified, upon delivery of the tax credit to the TCI, as a reduction in the carrying value of the subject property, net of allocated expenses. During the nine months ended September 30, 2015 and 2014, \$11.9 million and \$22.6 million of tax credits, net of costs and estimated put payments, respectively, were contributed by TCIs and were recorded as other liabilities in the consolidated balance sheets. During the nine months ended September 30, 2015 and 2014, \$6.3 million and \$29.2 million of tax credits had been delivered to the TCIs and were reclassified as a reduction of the carrying value of the subject property. Direct and incremental costs incurred in structuring the transaction, consisting of third-party legal, accounting and other professional fees, are deferred and will be recognized as an increase in the cost basis of the subject property upon the

recognition of the related tax credit as discussed above.

At September 30, 2015 and December 31, 2014, the Company determined that the special purpose entities owning two properties and one property under development, respectively, are VIEs, since there is insufficient capital to finance the remaining development activities without further subordinated financial support. The Company has determined it is the primary beneficiary of these VIEs, because it has the authority to direct the activities which most significantly impact their economic performance. Selected financial data of the VIEs at September 30, 2015 and December 31, 2014 consisted of the following (in thousands):

20

Table of Contents

| | September 30, 2015 | December 31, 2014 |
|--------------------------------|-----------------------|----------------------|
| Investment in real estate, net | \$81,579 | \$2,507 |
| Total assets | 96,985 | 24,478 |
| Total liabilities | 57,388 | 7,467 |

Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed

The Company reviews long-lived assets and certain identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The review of recoverability is based on an estimate of the future undiscounted cash flows (excluding interest charges) expected to result from the long-lived asset's use and eventual disposition. These cash flows consider factors such as expected future operating income, trends and prospects, as well as the effects of leasing demand, competition and other factors. If impairment exists due to the inability to recover the carrying value of a long-lived asset, an impairment loss is recorded to the extent that the carrying value exceeds the estimated fair-value of the property. The Company is required to make subjective assessments as to whether there are impairments in the values of its investments in long-lived assets. These assessments have a direct impact on the Company's net income because recording an impairment loss results in an immediate negative adjustment to net income. The evaluation of anticipated cash flows is highly subjective and is based in part on assumptions regarding future occupancy, rental rates and capital requirements that could differ materially from actual results in future periods. Although the Company's strategy is to hold its properties over the long-term, if the Company's strategy changes or market conditions otherwise dictate an earlier sale date, an impairment loss may be recognized to reduce the property to the lower of the carrying amount or fair-value, and such loss could be material.

During the nine months ended September 30, 2015, the Company recognized impairment losses of \$35.1 million, primarily related to the King of Prussia property, which was sold in May 2015. The property had been placed under active redevelopment to be held for long-term operations. However, in May 2015, the Company's strategy changed from actively redeveloping to selling with respect to this property as a result of market conditions which dictated an earlier sale. In connection with the change in strategy in May 2015, the Company recognized an impairment loss of \$32.3 million once the sale of the property became probable and the property was written down to its estimated fair value, less costs to sell. No gain or loss was recognized upon completion of the sale in May 2015.

Deferred Leasing Costs, Net

Leasing commissions and other direct costs associated with obtaining new or renewal leases are recorded at cost and amortized on a straight-line basis over the terms of the respective leases, with remaining terms ranging from less than one year to approximately 20 years as of September 30, 2015. Deferred leasing costs also include the net carrying value of acquired in-place leases and acquired management agreements.

Deferred leasing costs, net at September 30, 2015 consisted of the following (in thousands):

| | Balance at September 30, 2015 | Accumulated Amortization | Net |
|---|-------------------------------------|-----------------------------|-------------|
| Acquired in-place leases | \$421,408 | \$(293,370) |) \$128,038 |
| Acquired management agreements | 25,801 | (23,558) |) 2,243 |
| Deferred leasing and other direct costs | 143,935 | (47,260) |) 96,675 |
| | \$591,144 | \$(364,188) |) \$226,956 |

Deferred leasing costs, net at December 31, 2014 consisted of the following (in thousands):

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

| | Balance at December 31, 2014 | Accumulated Amortization | Net |
|---|------------------------------------|-----------------------------|-------------|
| Acquired in-place leases | \$415,389 | \$(271,782) |) \$143,607 |
| Acquired management agreements | 25,801 | (22,328) |) 3,473 |
| Deferred leasing and other direct costs | 111,290 | (38,657) |) 72,633 |
| | \$552,480 | \$(332,767) |) \$219,713 |

Investments

21

Table of Contents

Investments in equity securities, which are included in other assets on the accompanying consolidated balance sheets, consisted of the following (in thousands):

| | September 30, 2015 | December 31, 2014 |
|--|-----------------------|----------------------|
| Available-for-sale securities, historical cost | \$11,061 | \$10,280 |
| Unrealized gain, net | 454 | 48,341 |
| Available-for-sale securities, fair-value (1) | 11,515 | 58,621 |
| Privately-held securities, cost basis | 69,021 | 43,428 |
| Total equity securities | \$80,536 | \$102,049 |

(1) Determination of fair-value is classified as Level 1 in the fair-value hierarchy based on the use of quoted prices in active markets.

The Company holds investments in available-for-sale securities of certain publicly-traded companies. Changes in the fair-value of investments classified as available-for-sale are recorded in comprehensive income. The fair-value of the Company's equity investments in publicly-traded companies are based upon the closing trading price of the equity security as of the balance sheet date. Certain of these investments have fair-values less than the Company's cost basis, net of previous other-than-temporary impairment in these securities due to decreases in their respective stock prices during the nine months ended September 30, 2015. However, management has the intent and ability to retain the investments for a period of time sufficient to allow for an anticipated recovery in their market value. Management will continue to periodically evaluate whether any investment, the fair-value of which is less than the Company's cost basis, should be considered other-than-temporarily impaired. If other-than-temporary impairment is considered to exist, the related unrealized loss will be reclassified from accumulated other comprehensive loss and recorded as a reduction of net income.

The Company also holds investments in securities of certain privately-held companies and funds, which are recorded at cost basis due to the Company's lack of control or significant influence over such companies and funds.

During the three and nine months ended September 30, 2015, the Company realized gains of \$19.5 million and \$88.4 million, respectively, primarily from the sale of investments in certain publicly-traded companies. Realized gains on investments in available-for-sale securities are included in other income in the consolidated statements of income. The basis for which the cost of an investment sold and the amount reclassified out of accumulated other comprehensive income into earnings is determined by specific identification. In addition, during the nine months ended September 30, 2015, the Company realized a gain of \$11.4 million related to the collection of a note receivable that was previously fully reserved, which is also included in other income in the consolidated statements of income.

During the nine months ended September 30, 2015, the Company recorded impairment charges of \$2.7 million. Impairment charges are included as reduction to other income, net in the consolidated statements of income and primarily relate to the Company's investments in a privately-held company. Other than these investments, there were no identified events or changes in circumstances that may have a significant adverse effect on the carrying value of the Company's cost method investments and therefore, no evaluation of impairment was performed during the nine months ended September 30, 2015 on the Company's remaining cost method investments.

Construction Loan Receivable

The Company had a \$255.0 million interest in a \$355.0 million construction loan secured by first priority mortgages on a 1.1 million square foot laboratory, office and retail development project located in Boston, Massachusetts, which is 95% leased to Vertex Pharmaceuticals Incorporated to serve as its new corporate headquarters (the "Construction Loan"). In May 2014, the borrower repaid the then outstanding principal and accrued interest balance prior to

maturity, of which the Company's portion was approximately \$191.2 million.

Lease Termination

During the nine months ended September 30, 2015 and 2014, the Company recorded lease termination revenue, net of write-offs of lease intangibles, included in other revenue on the consolidated statements of income of approximately \$19.3 million and \$9.8 million, respectively. Lease termination revenue for the nine months ended September 30, 2015 primarily related to the early termination of Vertex Pharmaceuticals' leases at three of the Company's properties in Cambridge, Massachusetts in February 2015.

Table of Contents

Lease termination revenue for the nine months ended September 30, 2014 primarily related to the early termination of leases at the Company's 4570 Executive Drive property and two other properties.

Management's Estimates

Management has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reporting of revenue and expenses during the reporting period to prepare these consolidated financial statements in conformity with GAAP. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates under different assumptions or conditions.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue From Contracts With Customers ("ASU 2014-09"), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 states that "an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services." While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment. ASU 2014-09 is effective for the Company beginning January 1, 2017. However in July 2015, the FASB granted a one-year deferral of the effective date. The Company does not expect the adoption of this standard to have a significant impact on the consolidated financial statements as a substantial portion of the Company's revenue consists of rental income from leasing arrangements, which are specifically excluded from ASU 2014-09.

In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis ("ASU 2015-02"), which makes certain changes to both the variable interest model and the voting model, including changes to (1) the identification of variable interests (fees paid to a decision maker or service provider), (2) the variable interest entity characteristics for a limited partnership or similar entity and (3) the primary beneficiary determination. ASU 2015-02 is effective for the Company beginning January 1, 2016. Early adoption is permitted. The Company does not expect the adoption of this standard to have a significant impact on the consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs ("ASU 2015-03"), which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. ASU 2015-03 is effective for the Company beginning January 1, 2016. Early adoption is permitted. Upon adoption, the Company will apply the new standard on a retrospective basis and adjust the balance sheet of each individual period to reflect the period-specific effects of applying the new standard. The Company does not expect the adoption of this standard to have a significant impact on the consolidated financial statements.

3. Equity of the Parent Company

During the nine months ended September 30, 2015, the Parent Company issued restricted stock awards to the Company's employees and directors totaling 599,954 and 15,244 shares of common stock, respectively (263,914 shares of common stock were surrendered to the Company and subsequently retired in lieu of cash payments for taxes due on the vesting of restricted stock and 44,916 shares were forfeited during the same period), which are included in

the total of common stock outstanding as of the period end.

The Parent Company awarded units to certain of its executive officers (the "Performance Units"), which represent a contingent right to receive one share of the Parent Company's common stock if vesting conditions are satisfied. Outstanding Performance Units vest ratably over two or three year periods (each, a "Performance Period") based upon the Parent Company's total stockholder return relative to its peer group (the "Market Conditions"). The grant date fair-value of the Performance Units was estimated using a Monte Carlo simulation which considered the likelihood of achieving the Market Conditions. The expected value of the Performance Units on the grant date was determined by simulating the total stockholder return for the Parent Company and the peer group, considering the stock price variance for each of the peer group companies compared to each other and the Parent Company. In January 2015, 136,296 Performance Units which were originally granted to certain executive officers in January 2012 and represent the maximum number of Performance Units that could have vested, were forfeited as a result of the Parent Company's total stockholder return relative to its peer group for the three years ending December 31, 2014 being below the threshold for any payout. In addition, of the 203,144 Performance Units which were originally granted to certain executive officers in January

Table of Contents

2013 and represent the maximum number of Performance Units that could have vested, 13,215 Performance Units vested (resulting in the issuance of 13,215 shares of the Parent Company's common stock, of which 5,504 shares were surrendered to the Company and subsequently retired in lieu of cash payments for taxes due on such vesting) and the remaining 189,929 Performance Units were forfeited, based on the Parent Company's total stockholder return relative to its peer group for the two years ending December 31, 2014. During the nine months ended September 30, 2015, the Parent Company awarded 401,480 Performance Units which represent the maximum number of Performance Units that may vest over a three-year Performance Period ending December 31, 2017. The grant date fair-value of these awards of approximately \$5.8 million will be recognized as compensation expense on a straight-line basis over the three-year Performance Period. The total unearned compensation remaining on the Performance Units granted during the nine months ended September 30, 2015 to be expensed in future periods over a weighted-average term of 2.3 years was \$3.6 million as of September 30, 2015. No dividends will be paid or accrued on the Performance Units, and shares of the Parent Company's common stock will not be issued until vesting of the Performance Units occurs.

Common Stock, Operating Partnership Units and LTIP Units

As of September 30, 2015, the Company had outstanding 203,527,787 shares of the Parent Company's common stock and 5,083,400 and 314,824 operating partnership and LTIP units, respectively (excluding operating partnership units held by the Parent Company). A share of the Parent Company's common stock and the operating partnership and LTIP units have essentially the same economic characteristics as they share equally in the total net income or loss and distributions of the Operating Partnership.

Dividends and Distributions

The following table lists the dividends and distributions declared by the Parent Company and the Operating Partnership during the nine months ended September 30, 2015:

| Declaration Date | Securities Class | Amount Per Share/Unit | Period Covered | Dividend and Distribution Payable Date | Dividend and Distribution Amount (In thousands) |
|--------------------|---------------------------|-----------------------|------------------------------------|--|---|
| March 16, 2015 | Common stock and OP units | \$0.260 | January 1, 2015 to March 31, 2015 | April 15, 2015 | \$54,331 |
| June 15, 2015 | Common stock and OP units | \$0.260 | April 1, 2015 to June 30, 2015 | July 15, 2015 | \$54,331 |
| September 15, 2015 | Common stock and OP units | \$0.260 | July 1, 2015 to September 30, 2015 | October 15, 2015 | \$54,320 |

Changes in Accumulated Other Comprehensive Income / (Loss) by Component

The following table shows the changes in accumulated other comprehensive income / (loss) for the Parent Company for the nine months ended September 30, 2015, by component (in thousands):

| | Foreign currency translation adjustments | Unrealized gains on available-for-sale securities | (Loss) / gain on derivative instruments | Total |
|------------------------------|--|---|---|------------|
| Balance at December 31, 2014 | \$2,309 | \$ 37,705 | \$(42,228) | \$(2,214) |

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

| | | | | |
|---|--------|-----------|-------------|-------------|
| Other comprehensive (loss) / income before reclassifications | (1,473 |) 37,879 | (4,534 |) 31,872 |
| Amounts reclassified from accumulated other comprehensive income (1) | — | (85,767 |) 7,515 | (78,252 |
| Net other comprehensive (loss) / income | (1,473 |) (47,888 |) 2,981 | (46,380 |
| Net other comprehensive loss / (income) allocable to noncontrolling interests | 37 | 8,908 | (76 |) 8,869 |
| Balance as of September 30, 2015 | \$873 | \$ (1,275 |) \$(39,323 |) \$(39,725 |

Amounts reclassified from unrealized gain on available-for-sale securities are included in other income, net in the (1) consolidated statements of income. Amounts reclassified from loss on derivative instruments are included in interest expense, net in the consolidated statements of income. See Note 9 for further information.

Table of Contents

Noncontrolling Interests

Noncontrolling interests on the consolidated balance sheets of the Parent Company relate primarily to the OP units in the Operating Partnership that are not owned by the Parent Company. With respect to the noncontrolling interests in the Operating Partnership, noncontrolling interests with redemption provisions that permit the issuer to settle in either cash or common stock at the option of the issuer are further evaluated to determine whether temporary or permanent equity classification on the balance sheet is appropriate. Because the OP units comprising the noncontrolling interests contain such a provision, the Company evaluated this guidance, including the requirement to settle in unregistered shares, and determined that the OP units meet the requirements to qualify for presentation as permanent equity.

The Company evaluates individual redeemable noncontrolling interests for the ability to continue to recognize the noncontrolling interest as permanent equity in the consolidated balance sheets. Any redeemable noncontrolling interest that fails to qualify as permanent equity will be reclassified as temporary equity and adjusted to the greater of (1) the carrying amount, or (2) its redemption value at the end of the period in which the determination is made.

The redemption value of the OP units not owned by the Parent Company, had such units been redeemed at September 30, 2015, was approximately \$108.8 million based on the average closing price of the Parent Company's common stock of \$20.16 per share for the ten consecutive trading days immediately preceding September 30, 2015.

The following table shows the vested ownership interests in the Operating Partnership:

| | September 30, 2015 | | December 31, 2014 | | |
|--|-----------------------------|---------------------|-----------------------------|---------------------|---|
| | Operating Partnership Units | Percentage of Total | Operating Partnership Units | Percentage of Total | |
| BioMed Realty Trust | 202,258,307 | 97.5 | % 196,031,538 | 97.4 | % |
| Noncontrolling interest consisting of: | | | | | |
| Operating partnership and LTIP units held by employees and related parties | 2,638,638 | 1.3 | % 2,645,888 | 1.3 | % |
| Operating partnership and LTIP units held by third parties | 2,627,145 | 1.2 | % 2,627,145 | 1.3 | % |
| Total | 207,524,090 | 100.0 | % 201,304,571 | 100.0 | % |

4. Capital of the Operating Partnership

Operating Partnership Units and LTIP Units

As of September 30, 2015, the Operating Partnership had outstanding 208,611,187 operating partnership units and 314,824 LTIP units. The Parent Company owned 97.5% of the partnership interests in the Operating Partnership at September 30, 2015, is the Operating Partnership's general partner and is responsible for the management of the Operating Partnership's business. As the general partner of the Operating Partnership, the Parent Company effectively controls the ability to issue common stock of the Parent Company upon a limited partner's notice of redemption. In addition, the Parent Company has generally acquired OP units upon a limited partner's notice of redemption in exchange for shares of its common stock. The redemption provisions of OP units owned by limited partners that permit the Parent Company to settle in either cash or common stock at the option of the Parent Company are further evaluated in accordance with applicable accounting guidance to determine whether temporary or permanent equity classification on the balance sheet is appropriate. The Operating Partnership evaluated this guidance, including the requirement to settle in unregistered shares, and determined that these OP units meet the requirements to qualify for

presentation as permanent equity.

The redemption value of the OP units owned by the limited partners, not including the Parent Company, had such units been redeemed at September 30, 2015, was approximately \$108.8 million based on the average closing price of the Parent Company's common stock of \$20.16 per share for the ten consecutive trading days immediately preceding September 30, 2015.

Changes in Accumulated Other Comprehensive Income / (Loss) by Component

The following table shows the changes in accumulated other comprehensive income / (loss) for the Operating Partnership for the nine months ended September 30, 2015, by component (in thousands):

25

Table of Contents

| | Foreign currency translation adjustments | Unrealized gains on available- for-sale securities | (Loss) / gain on derivative instruments | Total |
|--|---|--|---|-------------|
| Balance at December 31, 2014 | \$2,367 | \$38,732 | \$(40,221) | \$878 |
| Other comprehensive (loss) / income before reclassifications | (1,473) | 37,879 | (4,534) | 31,872 |
| Amounts reclassified from accumulated other comprehensive income (1) | — | (85,767) | 7,515 | (78,252) |
| Net other comprehensive (loss) / income | (1,473) | (47,888) | 2,981 | (46,380) |
| Net other comprehensive income allocable to noncontrolling interest | — | 9,689 | — | 9,689 |
| Balance as of September 30, 2015 | \$894 | \$533 | \$(37,240) | \$(35,813) |

Amounts reclassified from unrealized gain on available-for-sale securities are included in other income, net in the (1) consolidated statements of income. Amounts reclassified from loss on derivative instruments are included in interest expense, net in the consolidated statements of income. See Note 9 for further information.

5. Debt

Debt of the Parent Company

The Parent Company does not hold any indebtedness. All debt is held directly or indirectly by the Operating Partnership; however, the Parent Company has guaranteed the Operating Partnership's Unsecured Senior Notes due 2016 (the "Notes due 2016"), Unsecured Senior Notes due 2019 (the "Notes due 2019"), Unsecured Senior Notes due 2020 (the "Notes due 2020"), Unsecured Senior Notes due 2022 (the "Notes due 2022"), Unsecured Senior Term Loan due 2017 (the "Term Loan due 2017"), Unsecured Senior Term Loan due 2018 (the "Term Loan due 2018") and unsecured line of credit.

Debt of the Operating Partnership

The following is a summary of the Operating Partnership's outstanding consolidated debt as of September 30, 2015 and December 31, 2014 (dollars in thousands):

Table of Contents

| | Stated Interest Rate | Effective Interest Rate | Principal Balance | | Maturity Date |
|---|----------------------------|-------------------------------|-----------------------|----------------------|-------------------|
| | | | September 30, 2015 | December 31, 2014 | |
| Mortgage Notes Payable | | | | | |
| 9900 Belward Campus Drive | 5.64 | % 3.99 | % \$10,373 | \$10,486 | July 1, 2017 |
| 9901 Belward Campus Drive | 5.64 | % 3.99 | % 12,773 | 12,913 | July 1, 2017 |
| 100 College Street | 2.40 | % 2.40 | % 108,224 | 82,210 | August 2, 2016 |
| 4320 Forest Park Avenue | 4.00 | % 2.70 | % — | 21,000 | June 30, 2015 |
| 300 George Street | 6.20 | % 4.91 | % 43,721 | 45,052 | July 1, 2025 |
| Hershey Center for Applied Research | 6.15 | % 4.71 | % 12,516 | 12,938 | May 5, 2027 |
| 500 Kendall Street (Kendall D) | 6.38 | % 5.45 | % 52,506 | 55,545 | December 1, 2018 |
| Shady Grove Road | 5.97 | % 5.97 | % 139,606 | 141,131 | September 1, 2016 |
| University of Maryland BioPark I | 5.93 | % 4.69 | % 15,483 | 16,056 | May 15, 2025 |
| University of Maryland BioPark II | 5.20 | % 4.33 | % 61,088 | 61,905 | September 5, 2021 |
| University of Maryland BioPark Garage | 5.20 | % 4.33 | % 4,598 | 4,660 | September 1, 2021 |
| University of Miami Life Science & Technology Park | 4.00 | % 2.89 | % 20,000 | 20,000 | February 1, 2016 |
| | | | 480,888 | 483,896 | |
| Unamortized premiums | | | 11,177 | 12,861 | |
| Mortgage notes payable, net | | | 492,065 | 496,757 | |
| Exchangeable Senior Notes (1) | 3.75 | % 3.75 | % — | 95,678 | January 30, 2015 |
| Notes due 2016 | 3.85 | % 3.99 | % 400,000 | 400,000 | April 15, 2016 |
| Notes due 2019 | 2.63 | % 2.72 | % 400,000 | 400,000 | May 1, 2019 |
| Notes due 2020 | 6.13 | % 6.27 | % 250,000 | 250,000 | April 15, 2020 |
| Notes due 2022 | 4.25 | % 4.36 | % 250,000 | 250,000 | July 15, 2022 |
| | | | 1,300,000 | 1,300,000 | |
| Unamortized discounts | | | (5,022 |) (6,097 |) |
| Unsecured senior notes, net | | | 1,294,978 | 1,293,903 | |
| Term Loan due 2017 - U.S. dollar (2) | 1.60 | % 2.39 | % 243,596 | 243,596 | March 30, 2017 |
| Term Loan due 2017 - GBP (2) | 1.91 | % 2.14 | % 151,530 | 155,730 | March 30, 2017 |
| Term Loan due 2018 | 1.40 | % 1.69 | % 350,000 | 350,000 | March 24, 2018 |
| Unsecured senior term loans | | | 745,126 | 749,326 | |
| Unsecured line of credit (3) | 1.31 | % 1.31 | % 463,000 | 84,000 | March 24, 2018 |
| Total consolidated debt | | | \$2,995,169 | \$2,719,664 | |

In January 2015, the entire remaining principal amount of the Operating Partnership's Exchangeable Senior Notes (1) due 2030 (the "Exchangeable Senior Notes") was exchanged for 5,764,026 shares of the Parent Company's common stock, at the request of the holders.

In August 2012, the Operating Partnership converted approximately \$156.4 million of outstanding borrowings into British pounds sterling ("GBP") equal to £100.0 million, which was designated as a net investment hedge to mitigate (2) the risk of fluctuations in foreign currency exchange rates. The principal balance represents the U.S. dollar amount based on the exchange rates of \$1.52 to £1.00 and \$1.56 to £1.00 at September 30, 2015 and December 31, 2014, respectively. The effective interest rate includes the impact of interest rate swap agreements (see Note 9 for further discussion of interest rate swap agreements).

At September 30, 2015, the Operating Partnership had additional borrowing capacity under the unsecured line of (3) credit of up to approximately \$437.0 million.

Exchangeable Senior Notes

During the nine months ended September 30, 2015, at the request of the holders that exercised their exchange right pursuant to the terms of the Exchangeable Senior Notes, the Parent Company issued 5,764,026 shares of its common stock in exchange for the remaining \$95.7 million in aggregate principal amount of the Exchangeable Senior Notes.

Table of Contents

Net Investment Hedge

The Operating Partnership designated the GBP denominated debt under the Term Loan due 2017 as a net investment hedge. The Operating Partnership entered into this net investment hedge to protect a designated amount of the Operating Partnership's net investment in a GBP functional currency subsidiary against the risk of adverse changes in the GBP/U.S. dollar exchange rate (foreign exchange risk). Variability in the GBP/U.S. dollar exchange rate impacts the Operating Partnership (a U.S. dollar functional currency entity) as the financial statements of the GBP functional currency subsidiary are translated each period, with the effect of changes in the GBP/U.S. dollar exchange rate being recorded in accumulated other comprehensive income. When the net investment is sold or substantially liquidated, the balance of the translation adjustment accumulated in other comprehensive income will be reclassified into earnings. The Operating Partnership is hedging the risk of changes in the U.S. dollar equivalent value of a portion of its net investment in its GBP subsidiary attributable to changes in the GBP/U.S. dollar exchange rate during the period of investment during which the hedging instrument is outstanding.

Maturities of Long-Term Debt

As of September 30, 2015, principal payments due for the Operating Partnership's consolidated indebtedness (excluding debt premiums and discounts) were as follows (in thousands):

| | |
|------------|-------------|
| 2015 | \$2,620 |
| 2016 | 676,633 |
| 2017 | 427,432 |
| 2018 | 860,804 |
| 2019 | 405,724 |
| Thereafter | 615,801 |
| | \$2,989,014 |

6. Earnings Per Share of the Parent Company

Through September 30, 2015 all of the Company's participating securities (including the OP units) received dividends/distributions at an equal dividend/distribution rate per share/unit. As a result, the portion of net income allocable to the weighted-average unvested restricted stock outstanding for the three and nine months ended September 30, 2015 and 2014 has been deducted from net income attributable to the Company to calculate basic earnings per share attributable to common stockholders. The calculation of diluted earnings per share for the three and nine months ended September 30, 2015 and 2014 includes the outstanding OP units (both vested and unvested) in the weighted-average shares, and net income attributable to noncontrolling interests in the Operating Partnership has been added back to net income attributable to the Company. For the three and nine months ended September 30, 2015 and 2014, the Performance Units were dilutive to the calculation of diluted earnings per share as calculated, assuming that September 30, 2015 and 2014 were the end dates of the respective Performance Units' Performance Periods. For the three and nine months ended September 30, 2015 and 2014, the unvested restricted stock was anti-dilutive to the calculation of diluted earnings per share and was therefore excluded. As a result, diluted earnings per share was calculated based upon net income attributable to the Company less net income allocable to unvested restricted stock and distributions in excess of earnings attributable to unvested restricted stock. In addition, for the nine months ended September 30, 2015, 393,631 shares issuable upon settlement of the exchange feature of the Exchangeable Senior Notes were anti-dilutive and were not included in the calculation of diluted earnings per share based on the "if converted" method. For the three and nine months ended September 30, 2014, 7,589,600 and 9,571,008 shares issuable upon settlement of the exchange feature of the Exchangeable Senior Notes, respectively, were anti-dilutive and were not included in the calculation of diluted earnings per share based on the "if converted" method. No other shares were

considered anti-dilutive for the three and nine months ended September 30, 2015 or 2014.

Computations of basic and diluted earnings per share (in thousands, except share data) were as follows:

28

Table of Contents

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|-------------------------------------|-------------|------------------------------------|-------------|
| | 2015 | 2014 | 2015 | 2014 |
| Basic earnings per share: | | | | |
| Net income attributable to the Company | \$28,203 | \$15,960 | \$69,126 | \$53,429 |
| Net income allocable and distributions in excess of earnings to participating securities | (349 |) (375 |) (1,091 |) (1,130 |
| Net income attributable to common stockholders - basic | \$27,854 | \$15,585 | \$68,035 | \$52,299 |
| Diluted earnings per share: | | | | |
| Net income attributable to common stockholders - basic | 27,854 | 15,585 | 68,035 | 52,299 |
| Net income attributable to noncontrolling interests in Operating Partnership | 734 | 429 | 1,804 | 1,464 |
| Net income attributable to common stockholders - diluted | \$28,588 | \$16,014 | \$69,839 | \$53,763 |
| Weighted-average common shares outstanding: | | | | |
| Basic | 202,210,976 | 194,022,619 | 201,746,167 | 191,988,661 |
| Incremental shares from: | | | | |
| Performance units | 192,384 | 146,800 | 178,401 | 255,607 |
| Operating partnership and LTIP units | 5,398,224 | 5,405,474 | 5,400,986 | 5,407,089 |
| Diluted | 207,801,584 | 199,574,893 | 207,325,554 | 197,651,357 |
| Basic and diluted earnings per share: | | | | |
| Net income per share attributable to common stockholders - basic and diluted | \$0.14 | \$0.08 | \$0.34 | \$0.27 |

7. Earnings Per Unit of the Operating Partnership

Through September 30, 2015, all of the Operating Partnership's participating securities received distributions at an equal distribution rate per unit. As a result, the portion of net income allocable to the weighted-average unvested OP units outstanding for the three and nine months ended September 30, 2015 and 2014 has been deducted from net income attributable to the Operating Partnership to calculate basic earnings per unit attributable to common unit holders. For the three and nine months ended September 30, 2015 and 2014, the unvested OP units were anti-dilutive to the calculation of earnings per unit and were therefore excluded from the calculation of diluted earnings per unit, and diluted earnings per unit was calculated based upon net income attributable to unit holders. For the three and nine months ended September 30, 2015 and 2014, the Performance Units were dilutive to the calculation of diluted earnings per unit as calculated, assuming that September 30, 2015 and 2014 were the end date of the respective Performance Units' Performance Periods. In addition, for the nine months ended September 30, 2015, 393,631 units issuable upon settlement of the exchange feature of the Exchangeable Senior Notes were anti-dilutive and were not included in the calculation of diluted earnings per unit based on the "if converted" method. For the three and nine months ended September 30, 2014, 7,589,600 and 9,571,008 units issuable upon settlement of the exchange feature of the Exchangeable Senior Notes, respectively, were anti-dilutive and were not included in the calculation of diluted earnings per unit based on the "if converted" method. No other units were considered anti-dilutive for the three and nine months ended September 30, 2015 or 2014.

Computations of basic and diluted earnings per unit (in thousands, except unit data) were as follows:

Table of Contents

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|-------------------------------------|-------------|------------------------------------|-------------|
| | 2015 | 2014 | 2015 | 2014 |
| Basic and diluted earnings per unit: | | | | |
| Net income attributable to the Operating Partnership | \$28,937 | \$16,389 | \$70,930 | \$54,893 |
| Net income allocable and distributions in excess of earnings to participating securities | (349 |) (375 |) (1,091 |) (1,130 |
| Net income attributable to unit holders - basic and diluted | \$28,588 | \$16,014 | 69,839 | 53,763 |
| Weighted-average units outstanding: | | | | |
| Basic | 207,609,199 | 199,428,093 | 207,147,153 | 197,395,750 |
| Incremental units from: | | | | |
| Performance units | 192,384 | 146,800 | 178,401 | 255,607 |
| Diluted | 207,801,583 | 199,574,893 | 207,325,554 | 197,651,357 |
| Basic and diluted earnings per unit: | | | | |
| Net income per unit attributable to unit holders - basic and diluted | \$0.14 | \$0.08 | \$0.34 | \$0.27 |

8. Investment in Unconsolidated Partnerships

The accompanying consolidated financial statements include investments in two limited liability companies with Prudential Real Estate Investors ("PREI"), 10165 McKellar Court, L.P. ("McKellar Court"), a limited partnership with Quidel Corporation, the tenant which occupies the McKellar Court property and BioPark Fremont, LLC ("BioPark Fremont"), a limited liability company with RPC Poppleton, LLC. General information on the PREI limited liability companies, the McKellar Court partnership and the BioPark Fremont limited liability company (each referred to in this footnote individually as a "partnership" and collectively as the "partnerships") as of September 30, 2015 was as follows:

| Name | Partner | Company's Ownership Interest | Company's Economic Interest | Date Acquired |
|--------------------|-----------------------|------------------------------------|-----------------------------------|--------------------|
| PREI I LLC (1) | PREI | 20% | 20% | April 4, 2007 |
| PREI II LLC | PREI | 20% | 20% | April 4, 2007 |
| McKellar Court (2) | Quidel Corporation | 22% | 22% | September 30, 2004 |
| BioPark Fremont | RPC Poppleton, LLC | 50% | 50% | May 31, 2013 |

PREI I LLC owns two properties in Cambridge, Massachusetts. In July 2015, a wholly-owned subsidiary of PREI I LLC refinanced its secured loan facility with \$139.0 million in previously outstanding borrowings into a new (1) secured loan with a principal amount of \$160.0 million, an interest rate equal to LIBOR plus 140 basis points, and a maturity date of August 1, 2020 (with two options to extend the maturity date for one year each at its discretion after satisfying certain conditions and paying an extension fee).

The Company's investment in the McKellar Court partnership (maximum exposure to losses) was approximately (2) \$11.7 million at September 30, 2015. The Company's economic interest in the McKellar Court partnership entitles it to 75% of the extraordinary cash flows after repayment of the partners' capital contributions and 22% of the operating cash flows.

The condensed combined balance sheets for all of the Company's unconsolidated partnerships were as follows (in thousands):

30

Table of Contents

| | September 30, 2015 | December 31, 2014 |
|---|-----------------------|----------------------|
| Assets: | | |
| Investments in real estate, net | \$263,410 | \$267,007 |
| Cash and cash equivalents (including restricted cash) | 9,725 | 6,057 |
| Other assets | 10,909 | 11,599 |
| Total assets | \$284,044 | \$284,663 |
| Liabilities and members' equity: | | |
| Mortgage notes payable and secured loan | \$173,142 | \$152,056 |
| Other liabilities | 19,226 | 9,020 |
| Members' equity | 91,676 | 123,587 |
| Total liabilities and members' equity | \$284,044 | \$284,663 |
| Company's investments in unconsolidated partnerships | \$29,367 | \$35,291 |

The selected data and results of operations for the unconsolidated partnerships were as follows (in thousands):

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------|-----------|-------------------|-----------|
| | September 30, | | September 30, | |
| | 2015 | 2014 | 2015 | 2014 |
| Total revenues | \$7,439 | \$18,173 | \$25,097 | \$27,386 |
| Total expenses | (7,546 |) (15,693 |) (25,600 |) (27,681 |
| Net (loss) / income | \$ (107 |) \$2,480 | \$ (503 |) \$ (295 |
| Company's equity in net income of unconsolidated partnerships | \$242 | \$733 | \$534 | \$585 |
| Fees earned by the Company (1) | \$263 | \$140 | \$536 | \$678 |

The Company acts as the operating member or partner, as applicable, and day-to-day manager for the partnerships. (1) The Company is entitled to receive fees for providing construction and development services (as applicable) and management services to the PREI joint ventures, which are reflected in tenant recoveries and other income in the consolidated statements of income.

9. Derivatives and Other Financial Instruments

The Company is exposed to the effect of changes in interest rates on the Operating Partnership's U.S. dollar-LIBOR-based and GBP-LIBOR-based debt. The Company limits this risk by following established risk management policies and procedures including the use of derivatives. The Company's objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements related to the Operating Partnership's LIBOR-based debt. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. The interest rate swaps hedge the Company's exposure to the variability on expected cash flows attributable to changes in interest rates. These interest rate swaps are currently intended to hedge interest payments associated with the Operating Partnership's Term Loan due 2017 and Term Loan due 2018.

As of September 30, 2015, the Company had deferred interest costs of approximately \$23.7 million in accumulated other comprehensive loss related to forward starting swaps, which were settled with the corresponding counterparties in 2009. The forward starting swaps were entered into to mitigate the Company's exposure to the variability in

expected future cash flows attributable to changes in future interest rates associated with a forecasted issuance of fixed-rate debt, with interest payments for a minimum of ten years. The deferred interest costs will be amortized as additional interest expense over a remaining period of approximately four years.

The following is a summary of the terms of the interest rate swaps and their respective fair-values (dollars in thousands):

31

Table of Contents

| | Notional Amount | Strike Rate | Effective Date | Expiration Date | Fair-Value(1) | |
|---------------------------|--------------------|-------------|--------------------|--------------------|-----------------------|----------------------|
| | | | | | September 30, 2015 | December 31, 2014 |
| Interest rate swaps | \$200,000 | 1.1630 % | March 30, 2012 | March 30, 2017 | \$(1,942) | \$(1,448) |
| Interest rate swaps | 200,000 | 0.7010 % | October 1, 2013 | October 1, 2016 | (620) | (186) |
| Interest rate swaps(2) | 75,765 | 0.7310 % | August 2, 2012 | March 30, 2017 | (113) | 63 |
| Interest rate swaps(2) | 75,765 | 0.7425 % | August 2, 2012 | March 30, 2017 | (99) | 45 |
| Total interest rate swaps | \$551,530 | | | | \$(2,774) | \$(1,526) |

- Fair-value of derivative instruments does not include any related accrued interest payable, which is included in accrued expenses on the accompanying consolidated balance sheets. Derivative valuations are classified in Level 2 of the fair-value hierarchy. Assets are included in other assets and liabilities are included in accounts payable, accrued expenses and other liabilities on the accompanying consolidated balance sheets.
- (1) Translation to U.S. dollars is based on exchange rates of \$1.52 to £1.00 and \$1.56 to £1.00 at September 30, 2015 and December 31, 2014, respectively.

For derivatives designated as cash flow hedges, the effective portion of changes in the fair-value of the derivative is initially reported in other comprehensive income (outside of earnings) and subsequently reclassified to earnings in the period in which the hedged forecasted transaction affects earnings. During the nine months ended September 30, 2015 and 2014, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt. The ineffective portion of the change in fair-value of the derivatives is recognized directly in earnings. No portion of the derivatives designated as cash flow hedges were classified as ineffective during the nine months ended September 30, 2015 or 2014.

The following is a summary of the amount of gain / (loss) recognized in other comprehensive income related to the derivative instruments (in thousands):

| | Three Months Ended September 30, 2015 | | Nine Months Ended September 30, 2015 | |
|--|---|----------|--|------------|
| | 2015 | 2014 | 2015 | 2014 |
| Amount of loss recognized in other comprehensive income (effective portion): | | | | |
| Cash flow hedges | | | | |
| Interest rate swaps | \$(1,854) | \$(726) | \$(4,534) | \$(3,426) |
| Amount of (loss) / income reclassified from accumulated other comprehensive loss to income (effective portion): | | | | |
| Cash flow hedges | | | | |
| Interest rate swaps (1) | \$(828) | \$895 | \$(2,550) | \$2,677 |
| Forward starting swaps (2) | (1,647) | 1,677 | (4,965) | 5,052 |
| Total interest rate swaps | \$(2,475) | \$2,572 | \$(7,515) | \$7,729 |
| Amount of gain / (loss) recognized in income (ineffective portion and amount excluded from effectiveness testing): | | | | |
| Other derivative instruments | 11 | (190) | 29 | (298) |
| Total gain / (loss) on derivative instruments | \$11 | \$(190) | \$29 | \$(298) |

(1)

Amount represents payments made to swap counterparties for the effective portion of interest rate swaps that were recognized as an increase to interest expense for the periods presented (the amount was recorded as an increase and corresponding decrease to accumulated other comprehensive loss in the same accounting period).

- (2) Amount represents reclassifications of deferred interest costs from accumulated other comprehensive loss to interest expense related to the Company's previously settled forward starting swaps.

10. Fair-Value of Financial Instruments

Table of Contents

The Company's disclosures of estimated fair-value of financial instruments at September 30, 2015 and December 31, 2014 were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair-value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair-value amounts.

The carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other liabilities approximate fair-value due to the short-term nature of these instruments.

The Company utilizes quoted market prices to estimate the fair-value of its fixed-rate and variable-rate debt, when available. If quoted market prices are not available, the Company calculates the fair-value of its mortgage notes payable and other fixed-rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed-rate debt, a market credit spread is added to the quoted yields on federal government treasury securities with similar terms to debt. In determining the current market rate for variable-rate debt, a market credit spread is added to the current effective interest rate. The carrying values of interest rate swaps are reflected at their fair-values.

At September 30, 2015 and December 31, 2014, the aggregate fair-value and the carrying value of the Company's financial instruments were as follows (in thousands):

| | September 30, 2015 | | December 31, 2014 | |
|----------------------------------|--------------------|----------------|-------------------|----------------|
| | Fair-Value (1) | Carrying Value | Fair-Value (1) | Carrying Value |
| Mortgage notes payable, net | \$496,173 | \$492,065 | \$502,115 | \$496,757 |
| Exchangeable Senior Notes | — | — | 134,619 | 95,678 |
| Notes due 2016, net | 403,600 | 399,704 | 411,600 | 399,304 |
| Notes due 2019, net | 384,080 | 398,210 | 398,280 | 397,873 |
| Notes due 2020, net | 267,500 | 248,640 | 283,250 | 248,450 |
| Notes due 2022, net | 244,900 | 248,423 | 258,250 | 248,275 |
| Term Loan due 2017 - U.S. dollar | 244,500 | 243,596 | 244,945 | 243,596 |
| Term Loan due 2017 - GBP (2) | 152,091 | 151,530 | 156,589 | 155,730 |
| Term Loan due 2018 | 350,430 | 350,000 | 350,557 | 350,000 |
| Unsecured line of credit | 462,431 | 463,000 | 83,866 | 84,000 |
| Derivative instruments (3) | 2,351 | 2,351 | 1,132 | 1,132 |
| Available-for-sale securities | 11,515 | 11,515 | 58,621 | 58,621 |

(1) Fair-values of debt and derivative instruments are classified in Level 2 of the fair-value hierarchy. Fair-value of available-for-sale securities are classified in Level 1 of the fair-value hierarchy.

(2) The principal balance represents the U.S. dollar amount based on the exchange rate of \$1.52 to £1.00 and \$1.56 to £1.00 at September 30, 2015 and December 31, 2014, respectively.

(3) The Company's derivative instruments are reflected in other assets and in accounts payable, accrued expenses and other liabilities on the accompanying consolidated balance sheets based on their respective balances (see Note 9).

11. Acquisitions

The Company acquired four properties during the nine months ended September 30, 2015. The table below reflects the purchase price allocation for these acquisitions (in thousands).

Table of Contents

| Property | Acquisition Date | Investments in Real Estate | Below Market Lease | In-Place Lease | Acquisition Date Fair-Value |
|---|-------------------|-------------------------------|--------------------------|-------------------|-----------------------------------|
| 307 Westlake | February 11, 2015 | \$85,733 | \$(1,824) | \$5,791 | \$89,700 |
| Towne Centre Technology Park (1) | May 5, 2015 | 84,181 | — | — | 84,181 |
| South Street Landing (1) (2) | July 24, 2015 | 21,352 | — | — | 21,352 |
| 21 Firstfield (1) | September 3, 2015 | 10,418 | (875) | 854 | 10,397 |
| Total | | \$201,684 | \$(2,699) | \$6,645 | \$205,630 |
| Weighted average intangible amortization life (in months) | | | 96 | 95 | |

(1) Amounts reflect preliminary purchase price allocations.

(2) Amount represents the initial investment in a development project which is expected to include a 267,941 square foot office and laboratory building, a 750 stall garage and 172 unit graduate student housing complex.

Revenues of approximately \$6.4 million and net income of \$4.6 million associated with the acquired properties are included in the consolidated statements of income for the three months ended September 30, 2015 for both the Parent Company and the Operating Partnership.

Revenues of approximately \$13.7 million and net income of \$8.8 million associated with the acquired properties are included in the consolidated statements of income for the nine months ended September 30, 2015 for both the Parent Company and the Operating Partnership.

12. Subsequent Events

Merger Agreement

On October 7, 2015, the Parent Company and the Operating Partnership entered into an Agreement and Plan of Merger (the “Merger Agreement”) with BRE Edison Holdings L.P. (“Parent”), BRE Edison L.P. (“Merger Sub I”) and BRE Edison Acquisition L.P. (“Merger Sub II”). The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein, Merger Sub II will merge with and into the Operating Partnership (the “Partnership Merger”), and the separate existence of Merger Sub II will cease and the Operating Partnership will be the surviving partnership in the Partnership Merger. Immediately following the effective time of the Partnership Merger (the “Partnership Merger Effective Time”), the Parent Company will merge with and into Merger Sub I (the “Company Merger” and, together with the Partnership Merger, the “Mergers”), and the separate existence of the Parent Company will cease and Merger Sub I will continue as the surviving company in the Company Merger. The Mergers and the other transactions contemplated by the Merger Agreement have been unanimously approved by our board of directors. Parent, Merger Sub I and Merger Sub II are affiliates of Blackstone Real Estate Partners VIII L.P., an affiliate of The Blackstone Group L.P.

Pursuant to the terms and conditions in the Merger Agreement, at the effective time of the Company Merger (the “Company Merger Effective Time”), each share of common stock of the Parent Company, other than shares held by any of the Parent Company’s subsidiaries or Parent, Merger Sub I or any of their respective subsidiaries, if any, that is issued and outstanding immediately prior to the Company Merger Effective Time will automatically be converted into the right to receive an amount in cash equal to \$23.75 (plus, if the Mergers are consummated after January 1, 2016, a per diem amount of approximately \$0.003 for each day from and after such date until (but not including) the closing date) (the “Per Company Share Merger Consideration”), without interest.

Pursuant to the terms and conditions in the Merger Agreement, at the Partnership Merger Effective Time, each OP unit in the Operating Partnership, other than OP units held by the Parent Company or any of the Parent Company’s subsidiaries or Parent, Merger Sub II or any of their respective subsidiaries, if any, that is issued and outstanding

immediately prior to the Partnership Merger Effective Time will automatically be converted into, and will be canceled in exchange for, the right to receive an amount in cash equal to the Per Company Share Merger Consideration, without interest, provided that, in lieu of receiving the Per Company Share Merger Consideration, each qualifying holder of partnership units may elect to receive one newly created 5.5% Series B Cumulative Preferred Unit in the surviving partnership per OP unit for all or a portion of such holder's OP units.

In addition, immediately prior to the Company Merger Effective Time, each outstanding restricted stock award of the Parent Company will automatically become fully vested and non-forfeitable, and all shares of common stock of the Parent Company represented thereby will be considered outstanding and subject to the right to receive the Per Company Share Merger Consideration (less any applicable income and employment taxes). In addition, immediately prior to the Company Merger Effective Time, each outstanding Performance Unit will automatically become earned and vested with respect to the number of shares of common stock

Table of Contents

subject to such Performance Unit based on the achievement of the applicable performance goals set forth in the award agreement governing such Performance Unit as of such date. Such earned and vested Performance Units will be canceled and, in exchange therefor, Parent will cause the surviving entity in the Company Merger to pay to each former holder an amount in cash, without interest, and less any applicable income and employment withholding taxes, equal to the Per Company Share Merger Consideration for each such Performance Unit. Each Performance Unit that does not become earned and vested based on achievement of the applicable performance goals will terminate without consideration immediately prior to the Company Merger Effective Time.

In connection with the transaction, the parties intend that the Operating Partnership will, at the request of Parent, use its commercially reasonable efforts to commence offers to purchase and related consent solicitations for one or more series of the Notes due 2016, Notes due 2019, Notes due 2020 and/or Notes due 2022 (collectively, the “Senior Notes”) and/or reasonably cooperate in effecting the giving of notices of optional redemption and the satisfaction and discharge or covenant defeasance of the Senior Notes on the closing date, in each case conditioned upon, among other things, the consummation of the Mergers. Details with respect to any such offers to purchase and related consent solicitations or redemptions will be set forth in the documents relating to any such transactions. The disclosure in this Quarterly Report on Form 10-Q is not an offer to purchase, a solicitation of consents or a notice of redemption, nor the solicitation of an offer to sell securities or to deliver consents.

The Merger Agreement also contains customary representations, warranties and covenants, including, among others, covenants by the Parent Company to conduct its business in all material respects in the ordinary course of business consistent with past practice, subject to certain exceptions, during the period between the execution of the Merger Agreement and the consummation of the Mergers. The obligations of the parties to consummate the Mergers are not subject to any financing condition or the receipt of any financing by Parent, Merger Sub I or Merger Sub II.

The consummation of the Mergers is subject to certain customary closing conditions, including, among others, approval of the Company Merger and the other transactions contemplated by the Merger Agreement by the affirmative vote of a majority of the outstanding shares of common stock of the Parent Company (the “Company Requisite Vote”) as of the record date for the special meeting of stockholders.

The Merger Agreement requires the Parent Company to convene a stockholders’ meeting for purposes of obtaining the Company Requisite Vote and to prepare and file a proxy statement with the U.S. Securities and Exchange Commission with respect to such meeting as promptly as practicable after the date of the Merger Agreement, which proxy statement will contain, subject to certain exceptions, our board of directors’ recommendation that the Parent Company’s stockholders vote in favor of the Company Merger and the other transactions contemplated by the Merger Agreement.

The Parent Company has agreed not to solicit or enter into an agreement regarding a Company Acquisition Proposal (as defined in the Merger Agreement), and, subject to certain exceptions, is not permitted to enter into discussions or negotiations concerning, or provide non-public information to a third party in connection with, any Company Acquisition Proposal. However, the Parent Company may, prior to obtaining the Company Requisite Vote, engage in discussions or negotiations and provide non-public information to a third party which has made an unsolicited written bona fide Company Acquisition Proposal if our board of directors determines in good faith, after consultation with outside legal counsel and financial advisors, that such Company Acquisition Proposal constitutes, or could reasonably be expected to lead to, a Superior Proposal (as defined in the Merger Agreement).

Prior to the approval of the Company Merger and the other transactions contemplated by the Merger Agreement by the Parent Company’s stockholders, our board of directors may, in certain circumstances, effect an Adverse Recommendation Change (as defined in the Merger Agreement), subject to complying with specified notice and other conditions set forth in the Merger Agreement.

The Merger Agreement may be terminated under certain circumstances by the Parent Company, including prior to obtaining the Company Requisite Vote, if, after following certain procedures and adhering to certain restrictions, our board of directors has effected an Adverse Recommendation Change in connection with a Superior Proposal and the Parent Company enters into a definitive agreement providing for the implementation of a Superior Proposal. In addition, Parent may terminate the Merger Agreement under certain circumstances and subject to certain restrictions, including if our board of directors effects, or has resolved to effect, an Adverse Recommendation Change. Upon a termination of the Merger Agreement, under certain circumstances, the Parent Company will be required to pay a termination fee to Parent of \$160.0 million. In certain other circumstances, Parent will be required to pay the Parent Company a termination fee of \$460.0 million upon termination of the Merger Agreement. Blackstone Real Estate Partners VIII L.P. (the “Sponsor”), an affiliate of The Blackstone Group L.P., has guaranteed certain payment obligations of Parent under the Merger Agreement up to \$460.0 million.

Following the announcement of the execution of the Merger Agreement, three purported class actions related to the proposed Mergers, Noon v. BioMed Realty Trust, Inc., et al., No. 24-C-15-005174, Lipovich v. Gold, et al., No. 24-C-15-005174 and Schwartz

Table of Contents

v. BioMed Realty Trust, Inc., et al., No. 24-C-15-005477, were filed in the Circuit Court of Maryland for Baltimore City, against the Company, Parent, Merger Sub I, Merger Sub II, the Sponsor, and the members of the Company's board of directors, alleging, among other things, that the directors breached their fiduciary duties in connection with the Merger Agreement. Refer to Part II, Item 1, "Legal Proceedings" for further details. The Company is unable to predict the developments in, outcome of, and/or economic or other consequences of this litigation or predict the developments in, outcome of, and/or other consequences arising out of any potential future litigation or government inquiries related to the Mergers.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

As used herein, the terms "we," "us," "our" or the "Company" refer to BioMed Realty Trust, Inc., a Maryland corporation, and any of our subsidiaries, including BioMed Realty, L.P., a Maryland limited partnership of which BioMed Realty Trust, Inc. is the parent company and general partner, which may be referred to herein as the "operating partnership." The following discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere in this report. We make statements in this report that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, statements pertaining to our capital resources, portfolio performance and results of operations contain forward-looking statements. Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise, and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). You can identify forward-looking statements by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates" or the negative of these words and phrases or similar words or phrases. You can also identify forward-looking statements by discussions of strategy, plans or intentions. The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: the ability of the Company to obtain required stockholder or regulatory approvals required to consummate the Mergers and other transactions contemplated by the Merger Agreement; the satisfaction or waiver of other conditions to closing in the definitive agreement for the Mergers and other transactions contemplated by the Merger Agreement; unanticipated difficulties or expenditures relating to the Mergers and other transactions contemplated by the Merger Agreement; the response of business partners and competitors to the announcement of the Mergers; potential difficulties in employee retention as a result of the announcement and pendency of the Mergers; legal proceedings that have been, or may be instituted against the Company and others related to the Mergers and other transactions contemplated by the Merger Agreement; adverse economic or real estate developments in the life science industry or in our target markets, including the inability of our tenants to obtain funding to run their businesses; our dependence upon significant tenants; our failure to obtain necessary outside financing on favorable terms or at all, including the continued availability of our unsecured line of credit; general economic conditions, including downturns in the foreign, domestic and local economies; changes in interest rates and foreign currency exchange rates; volatility in financial and securities markets; defaults on or non-renewal of leases by tenants; our inability to compete effectively; increased operating costs; our inability to successfully complete real estate acquisitions, developments and dispositions; risks and uncertainties affecting property development and construction; risks associated with tax credits, grants and other subsidies to fund development activities; our failure to effectively manage our growth and expansion into new markets or to successfully operate acquired properties and companies; our ownership of properties outside of the United States that subject us to different and potentially greater risks than those associated with our domestic operations; risks associated with our investments in loans, including borrower defaults and potential principal losses; reductions in asset valuations and related impairment charges; the loss of services of one or more of our executive officers; our failure to qualify or continue to qualify as a REIT; our failure to maintain our investment grade corporate credit ratings or a downgrade in our investment grade corporate credit ratings from one or more of the rating agencies; government approvals, actions and initiatives, including the need for compliance with environmental requirements; the effects of earthquakes and other natural disasters; lack of or insufficient amounts of insurance; risks associated

with security breaches and other disruptions to our information technology networks and related systems; and changes in real estate, zoning and other laws and increases in real property tax rates. Any forward-looking statement speaks only as of the date of this Quarterly Report on Form 10-Q. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or developments, future events or otherwise. The risks included here are not exhaustive, and additional factors could adversely affect our business and financial performance, including factors and risks included in other sections of this report. We discussed a number of material risks in our annual report on Form 10-K for the year ended December 31, 2014. Those risks continue to be relevant to our performance and financial condition. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on our company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue

Table of Contents

reliance on forward-looking statements as a prediction of actual results. A discussion of additional risks related to our business can be found below under Part II, Item 1A, "Risk Factors."

Pending Mergers

See Note 12 of the Notes to Consolidated Financial Statements included elsewhere herein for a discussion of the pending merger transaction to which the Company and the operating partnership are parties. The Mergers are expected to close during the first quarter of 2016, although closing is subject to various conditions, including the approval of the Company Merger by our common stockholders, and therefore, we cannot provide any assurance that the Mergers will close in a timely manner or at all.

Our ability to execute on our business plan could be adversely impacted by operating restrictions included in the Merger Agreement, including restrictions on acquiring new assets and raising additional capital. We have incurred and will incur a variety of merger-related costs which while not recurring in nature will not be recoverable if the Mergers are not consummated.

Overview

We operate as a fully integrated, self-administered and self-managed REIT focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry. Our tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. Our properties are generally located in markets with well-established reputations as centers for scientific research, including Boston, San Francisco, San Diego, Maryland, New York / New Jersey, Pennsylvania, North Carolina, Seattle, Cambridge (United Kingdom) and research parks located near or adjacent to universities and their related medical systems.

At September 30, 2015, we owned or had interests in a portfolio of properties with an aggregate of approximately 18.9 million rentable square feet.

The following reflects the classification of our properties between operating properties, active new construction (properties that are currently under development through ground up construction), active redevelopment (properties that we are currently preparing for their intended use, and accordingly are capitalizing interest and other costs as of the end of the quarter), unconsolidated partnership portfolio (properties which we partially own, but are not included in our consolidated financial statements) and land bank (representing properties engaged in activities related to planning, entitlement or other preparations for future development, and management's estimates of rentable square footage if development of these properties was undertaken) at September 30, 2015:

| | Gross Book Value (In thousands) | Buildings | Rentable Square Feet | Leased % | |
|--------------------------------------|---------------------------------------|-----------|-------------------------|----------|---|
| Operating portfolio | 6,206,086 | 179 | 16,445,488 | 93.4 | % |
| Active new construction | 260,119 | 11 | 1,884,346 | 71.6 | % |
| Active redevelopment | 55,907 | 3 | 182,866 | — | % |
| Unconsolidated partnership portfolio | 29,367 | 3 | 355,080 | 99.9 | % |
| Land bank (1) | 279,973 | — | 6,381,500 | — | |
| Total portfolio | \$6,831,452 | 196 | 25,249,280 | | |

(1) Includes properties engaged in activities related to planning, entitlement, or other preparations for future development.

Factors Which May Influence Future Operations

Our long-term corporate strategy is to continue to focus on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry. As of September 30, 2015, our total operating portfolio was 93.4% leased to 385 tenants. As of December 31, 2014, our total operating portfolio was 89.2% leased to 327 tenants.

Our leasing strategy for 2015 focuses on leasing vacant space, negotiating renewals for leases scheduled to expire during the year, and identifying new tenants or existing tenants seeking additional space to occupy the spaces for which we are unable to negotiate such renewals. We may proceed with additional new developments and acquisitions, as real estate and capital market conditions permit. As of September 30, 2015, leases representing 1.6% and 4.1% of our leased square feet were scheduled to expire during 2015 and 2016, respectively. The success of our leasing and development strategy depends on, among other things, general economic conditions, real estate market conditions and life science industry trends in our target markets in the United States and the United Kingdom.

Table of Contents

As a result of changing market conditions and the recent economic recession, we believe that the fair-values of some of our properties may have declined below their respective carrying values. However, to the extent that a property has a substantial remaining estimated useful life and management does not believe that the property will be disposed of prior to the end of its useful life, it would be unusual for undiscounted cash flows to be insufficient to recover the property's carrying value. We presently have the ability and intent to continue to own and operate our existing portfolio of properties and estimated undiscounted future cash flows from the operation of the properties are expected to be sufficient to recover the carrying value of each property. Accordingly, we do not believe that the carrying value of any of our properties is impaired. If our ability and/or our intent with regard to the operation of our properties otherwise dictate an earlier sale date, an impairment loss may be recognized to reduce the property to fair-value and such loss could be material.

A discussion of additional factors which may influence future operations can be found below under Part II, Item 1A, "Risk Factors," and in our annual report on Form 10-K for the year ended December 31, 2014.

Critical Accounting Policies

A complete discussion of our critical accounting policies can be found in our annual report on Form 10-K for the year ended December 31, 2014.

Results of Operations**Leasing Activity**

During the nine months ended September 30, 2015, we executed 156 leasing transactions representing 3,358,625 square feet, including 106 new leases totaling 2,781,209 square feet and 50 leases amended to extend their terms totaling 577,416 square feet. The following table summarizes our leasing activity, including leasing activity in our unconsolidated portfolio, during the nine months ended September 30, 2015:

| | Leased Square Feet | Current annualized base rent per leased square foot (1) | Current annualized base rent per leased square foot - GAAP basis (2) |
|---|--------------------|---|--|
| Leased square feet as of December 31, 2014 | 15,669,843 | | |
| Acquisitions | 167,942 | \$35.63 | \$39.47 |
| Expirations and terminations | (1,868,948) | 36.34 | 34.00 |
| Forward-lease delivery (3) | 192,505 | 36.74 | 39.24 |
| Renewals and extensions | 577,416 | 31.63 | 33.52 |
| New leases (4) | 2,320,121 | 30.45 | 31.90 |
| Leased square feet as of September 30, 2015 | 17,058,879 | | |
| Forward-leased square feet as of December 31, 2014 (3) | 179,149 | | |
| Forward-lease acquisitions | 10,524 | \$23.11 | \$23.63 |
| Forward-lease new leases - second generation (3) (5) | 461,088 | 48.38 | 59.35 |
| Forward-lease delivery (3) | (192,505) | 36.74 | 39.24 |
| Forward-leased square feet as of September 30, 2015 (3) | 458,256 | | |

Current annualized base rent per leased square foot is the monthly contractual rent per leased square foot as of the (1) period end, or if rent has not yet commenced, the first monthly rent payment per leased square foot due at each rent commencement date, multiplied by 12 months.

(2)

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

Current annualized base rent per leased square foot - GAAP basis is the monthly contractual rent per square foot as of the period end, or if rent has not yet commenced, the first monthly rent payment per square foot due at each rent commencement date, multiplied by 12 months (as adjusted for straight line rent, fair-value lease revenue and lease incentive revenue).

- (3) Leases on space which is currently occupied and where the leases are expected to commence upon vacancy of the existing tenants.

38

Table of Contents

- Includes leases on space which, in management's evaluation, require significant improvements to prepare or (4) condition the premises for its intended purpose or enhance the value of the property. This generally includes capital expenditures for active new construction, active redevelopment or repositioning a property.
 (5) Leases which are not considered by management to be first generation leases.

The following table summarizes our leasing activity and associated leasing costs for the nine months ended September 30, 2015:

| | Number of leases | Square feet | Free rent months | Tenant improvement costs per square foot (1) | Landlord costs per square foot (1) | Leasing commission costs per square foot (1) |
|--------------------------|------------------|-------------|------------------|--|------------------------------------|--|
| Renewals and extensions | 50 | 577,416 | 0.7 | \$8.72 | \$0.55 | \$6.70 |
| New leases (2) | 106 | 2,781,209 | 3.0 | 90.05 | 62.61 | 9.25 |
| Total / weighted-average | 156 | 3,358,625 | 2.6 | \$76.07 | \$51.94 | \$8.81 |

- (1) Based on management estimates. Assumes all tenant improvement, landlord and commission costs are paid in the calendar year in which the lease is executed, which may be different than the year in which they are actually paid.
 New leases - second generation were leased at a weighted-average current annualized base rent of \$49.69 per square foot, representing an increase of 20.5% over the previously expiring rents on a GAAP basis primarily due to (2) improvements in real estate market conditions, higher demand from life science tenants and higher tenant improvement allowances. Includes forward-lease new leases - second generation.

Active New Construction and Redevelopment

The following table summarizes our consolidated properties under active new construction and redevelopment at September 30, 2015 (dollars in thousands):

| Property | Rentable Square Feet | Percent Leased | Investment to Date (1) | Estimated Total Investment (2) | Estimated In-Service Date (3) |
|--------------------------------|----------------------|----------------|------------------------|--------------------------------|-------------------------------|
| Active New Construction | | | | | |
| South Street Landing (4) | 267,941 | 100.0 | % \$37,100 | \$185,000 | Q3 2016 - Q3 2017 |
| i3 | 316,000 | — | % 65,000 | 181,500 | Q3 2017 |
| Lincoln Centre (5) | 360,000 | 100.0 | % 35,800 | 147,000 | Q3 2017 & Q3 2018 |
| Chesterfield | 284,462 | 49.9 | % 9,100 | 86,000 | Q4 2017 |
| Granta Park II | 155,000 | 100.0 | % 3,000 | 76,000 | Q4 2017 |
| 500 Fairview Avenue | 122,702 | 37.8 | % 37,700 | 74,500 | Q1 2016 |
| Wake 60 | 283,250 | 100.0 | % 22,600 | 55,300 | Q3 2016 |
| Granta Park | 94,991 | 100.0 | % 100 | 52,000 | Q1 2017 |
| Total / weighted-average | 1,884,346 | 71.6 | % \$210,400 | \$857,300 | |
| Active Redevelopment | | | | | |
| Sidney Street/40 Erie Street | 289,468 | 36.3 | % \$119,500 | \$206,000 | Q4 2015 - 2017 |
| Towne Centre Technology Park | 182,866 | — | % 55,400 | 105,000 | Q1 2016 - 2017 |
| Total / weighted-average | 472,334 | 22.3 | % \$174,900 | \$311,000 | |
| Total | | | \$385,300 | | |

Includes amounts paid for acquiring the property, landlord improvements, tenant improvement allowances and (1) capitalized payroll, interest, ground rent and operating expenses, but excludes any amounts accrued as of September 30, 2015.

(2)

Includes construction costs associated with speculative leasing and forecasted capitalized payroll, interest, ground rent and operating expenses.

Management's estimate of the time in which construction is substantially completed. A project is considered (3) substantially complete and held available for occupancy upon the completion of tenant improvements, but no later than one year from c

Table of Contents

cessation of major construction activity. Upon completion, management expects the property to enter the same property portfolio one year subsequent to the in-service date.

(4) Upon completion of development, South Street Landing is expected to include a 267,941 square foot office and laboratory building, a 750 stall garage and a 172 unit graduate student housing complex.

(5) Phase I of the project is comprised of 200,000 square feet and is estimated to be delivered in the third quarter of 2017. Phase II comprising 160,000 square feet is estimated to be delivered in the third quarter of 2018.

The following summarizes our capital expenditures during the nine months ended September 30, 2015 and 2014 (in thousands):

| | Nine Months Ended | | | Percent Change | |
|--|-------------------|-----------|------------|----------------|---|
| | September 30, | | Change | | |
| | 2015 | 2014 | | | |
| Active new construction | \$172,153 | \$183,658 | \$(11,505) | (6.3) | % |
| Tax credit funding receipts, net of deferred costs | (11,938) | (22,557) | \$10,619 | (47.1) | % |
| Land bank | 8,341 | 14,685 | (6,344) | (43.2) | % |
| Active redevelopment | 9,506 | 4,534 | 4,972 | 109.7 | % |
| Tenant improvements - first generation | 35,588 | 31,093 | 4,495 | 14.5 | % |
| Recurring capital expenditures and second generation tenant improvements (1) | 60,378 | 46,291 | 14,087 | 30.4 | % |
| Other capital | 21,195 | 20,455 | 740 | 3.6 | % |
| Total capital expenditures | \$295,223 | \$278,159 | \$17,064 | 6.1 | % |

Recurring capital expenditures exclude (a) items associated with the expansion of a building or its improvements, (b) renovations to a building which change the underlying classification of the building, incurred to prepare or (1) condition the premises for its intended purpose (for example, from office to laboratory) or (c) capital improvements that represent an addition to the property rather than the replacement of property, plant or equipment. Includes revenue enhancing and non-revenue enhancing recurring capital expenditures.

Total capital expenditures were \$295.2 million and \$278.2 million for the nine months ended September 30, 2015 and 2014, respectively. See the section entitled "Liquidity and Capital Resources of BioMed Realty, L.P." below for further information on obligations for capital expenditures expected to be incurred in the future.

Comparison of the Three Months Ended September 30, 2015 to the Three Months Ended September 30, 2014

The following table sets forth historical financial information of the operations for same properties (all properties except properties held for sale, previous same properties, development properties, new properties and other entities), previous same properties (properties previously included in the same property portfolio during the three months ended September 30, 2014 that are now in the land bank), development properties (properties that were entirely or primarily under active new construction during either of the three months ended September 30, 2015 or 2014), new properties (properties that were not owned for each of the three months ended September 30, 2015 and 2014 and were not previous same properties or development properties) and other entities (legal entities performing corporate level functions and properties that were sold during or in between the comparative periods (dollars in thousands, except on a per square foot basis):

Table of Contents

| For the Three Months Ended September 30, 2015 | | | | | | | | | | |
|--|--------------------|----------------------|------------|-------------|-------------------|-----------|------------|---|--|--|
| | Same Properties | Previous Same (1) | Total | Development | New Properties | Other (2) | Total | | | |
| Rentable square feet | 14,987,573 | — | 14,987,573 | 3,356,123 | 169,004 | N/A | 18,512,700 | | | |
| Percent of total portfolio | 81.0 | % — | % 81.0 | % 18.1 | % 0.9 | % N/A | 100.0 | % | | |
| Percent leased | 92.8 | % — | % 92.8 | % 78.2 | % 99.4 | % N/A | 90.2 | % | | |
| For the Three Months Ended September 30, 2015 | | | | | | | | | | |
| | Same Properties | Previous Same (1) | Total | Development | New Properties | Other (2) | Total | | | |
| Rental revenue | \$ 114,439 | \$— | \$ 114,439 | \$ 7,428 | 1,491 | \$(26) | \$ 123,332 | | | |
| Tenant recoveries | 45,572 | — | 45,572 | 1,187 | 533 | 247 | 47,539 | | | |
| Other revenue (3) | — | — | — | — | — | 3,477 | 3,477 | | | |
| Total revenues | 160,011 | — | 160,011 | 8,615 | 2,024 | 3,698 | 174,348 | | | |
| Rental operations | 55,542 | 278 | 55,820 | 3,537 | 468 | 2,244 | 62,069 | | | |
| Net operating income / (loss) | 104,469 | (278) | 104,191 | 5,078 | 1,556 | 1,454 | 112,279 | | | |
| Adjustments to cash basis (4) | (3,059) | \$— | (3,059) | (3,197) | (213) | 33 | (6,436) | | | |
| Net operating income - cash basis | \$ 101,410 | \$(278) | \$ 101,132 | \$ 1,881 | \$ 1,343 | \$ 1,487 | \$ 105,843 | | | |
| Rental revenue - cash basis (5) | \$ 109,691 | \$— | \$ 109,691 | \$ 4,066 | \$ 1,278 | \$ 8 | \$ 115,043 | | | |
| For the Three Months Ended September 30, 2014 | | | | | | | | | | |
| | Same Properties | Previous Same (1) | Total | Development | New Properties | Other (2) | Total | | | |
| Rentable square feet | 14,987,573 | 107,231 | 15,094,804 | 1,409,960 | — | 332,812 | 16,504,764 | | | |
| Percent of total portfolio | 90.8 | % 0.6 | % 91.4 | % 8.6 | % — | % 2.0 | % 100.0 | % | | |
| Percent leased | 90.7 | % 71.0 | % 90.7 | % 83.8 | % — | % 100.0 | % 90.3% | | | |
| For the Three Months Ended September 30, 2014 | | | | | | | | | | |
| | Same Properties | Previous Same (1) | Total | Development | New Properties | Other (2) | Total | | | |
| Rental revenue | \$ 115,068 | \$ 805 | \$ 115,873 | \$ 971 | — | \$ 5,994 | \$ 122,838 | | | |
| Tenant recoveries | 41,850 | 216 | 42,066 | 178 | — | 382 | 42,626 | | | |
| Other revenue (3) | — | — | — | — | — | 3,452 | 3,452 | | | |
| Total revenues | 156,918 | 1,021 | 157,939 | 1,149 | — | 9,828 | 168,916 | | | |
| Rental operations | 50,823 | 502 | 51,325 | 994 | — | 2,580 | 54,899 | | | |
| Net operating income | 106,095 | 519 | 106,614 | 155 | — | 7,248 | 114,017 | | | |
| Adjustments to cash basis (4) | (449) | \$ 623 | 174 | (325) | — | (204) | (355) | | | |
| Net operating income - cash basis | \$ 105,646 | \$ 1,142 | \$ 106,788 | \$(170) | \$— | \$ 7,044 | \$ 113,662 | | | |
| Rental revenue - cash basis (5) | \$ 113,447 | \$ 1,428 | \$ 114,875 | \$ 478 | \$— | \$ 5,790 | \$ 121,143 | | | |

- (1) Properties previously included in same property portfolio in prior year quarter that are now in the land bank, comprised of the 700 and 750 Gateway properties.
Other includes legal entities performing corporate level functions and properties that were sold during, or in
- (2) between the comparative periods, which includes revenue and operating expenses relating to the 65 West Watkins Mill Road property, which was sold on September 24, 2015, and the 9911 Belward Campus Drive property, which was sold on December 9, 2014.
Includes lease termination revenue of \$3.1 million and \$3.3 million for the three months ended September 30, 2015 and 2014, respectively. Lease termination revenue for the three months ended September 30, 2015 is primarily
- (3) related to an early termination at our 9885 Towne Centre Drive property. Lease termination revenue for the three months ended September 30, 2014 primarily related to the early termination of leases at our 50 Hampshire and Granta Park properties.

Table of Contents

Adjustments to cash basis exclude adjustments to expenses accrued in rental operations, but include straight line (4) rents, fair-value lease revenue, lease incentive revenue, bad debt expense and rental cash receipts deferred for GAAP purposes.

(5) Rental revenues - cash basis calculated by adjusting for straight-line rents, lease incentives, fair value lease revenue and rental cash receipts deferred for GAAP purposes.

The following table provides a reconciliation of net operating income - cash basis to net income for the three months ended September 30, 2015 and 2014 (in thousands):

| | Three Months Ended | | | Percent | |
|---|-----------------------|-----------|-----------|---------|----|
| | September 30, 2015 | 2014 | Change | Change | |
| Net operating income - cash basis | \$105,843 | \$113,662 | \$(7,819) | (6.9) |)% |
| Adjustments to cash basis | 6,436 | 355 | 6,081 | 1,713.0 | % |
| Net operating income | 112,279 | 114,017 | (1,738) | (1.5) |)% |
| Unallocated expense: | | | | | |
| Depreciation and amortization expense | 64,953 | 64,452 | 501 | 0.8 | % |
| General and administrative expense | 13,166 | 12,768 | 398 | 3.1 | % |
| Acquisition-related expenses | 720 | 487 | 233 | 47.8 | % |
| Income from operations | 33,440 | 36,310 | (2,870) | (7.9) |)% |
| Equity in net income of unconsolidated partnerships | 242 | 733 | (491) | (67.0) |)% |
| Interest expense, net | (21,228) | (22,215) | 987 | (4.4) |)% |
| Gain on sale of real estate | 1,869 | — | 1,869 | N/A | |
| Other income, net | 18,770 | 2,148 | 16,622 | 773.8 | % |
| Net income | \$33,093 | \$16,976 | \$16,117 | 94.9 | % |

Net Operating Income. Net operating income decreased \$1.7 million to \$112.3 million for the three months ended September 30, 2015 compared to \$114.0 million for the three months ended September 30, 2014. Excluding the impact of lease termination revenue for both periods and the operating results of the 65 West Watkins Mill Road property, which was sold in September 2015, and the 9911 Belward Campus Drive property, which was sold in December 2014, net operating income increased by \$4.1 million. This net increase was primarily attributable to the following:

The placement of properties that were previously under development into service contributed an increase of \$4.9 million in net operating income for the three months ended September 30, 2015 compared to the three months ended September 30, 2014;

The acquisition of two operating properties totaling approximately 169,000 square feet in 2015 contributed an additional \$1.6 million in net operating income for the three months ended September 30, 2015 compared to the three months ended September 30, 2014;

The increase was partially offset by a \$2.4 million decrease in same property and previous same property net operating income primarily due to the early terminations of two tenants occupying a total of 493,366 square feet at four properties located in Cambridge, Massachusetts during the three months ended June 30, 2015 and the placement of properties that were previously included in the same property portfolio into the land bank during the three months ended June 30, 2015.

Depreciation and Amortization Expense. Depreciation and amortization expense increased \$501,000 to \$65.0 million for the three months ended September 30, 2015 compared to \$64.5 million for the three months ended September 30, 2014. The increase was primarily due to the placement of four properties totaling 913,349 square feet into service and

the acquisition of two operating properties totaling 169,000 square feet with an acquisition date fair-value of \$100.1 million during 2015, partially offset by the sale of our 65 West Watkins Mill Road property in September 2015 and 9911 Belward Campus Drive property in December 2014.

General and Administrative Expenses. General and administrative expenses increased \$398,000 to \$13.2 million for the three months ended September 30, 2015 compared to \$12.8 million for the three months ended September 30, 2014. The increase was primarily due to professional fees incurred in connection with the proposed Mergers with affiliates of Blackstone Real Estate Partners VIII L.P., and higher staffing levels and compensation associated with our above-plan leasing and financial performance, partially offset by higher capitalized payroll related to increased development in 2015.

Table of Contents

Interest Expense, Net. Interest cost incurred for the three months ended September 30, 2015 totaled \$27.9 million compared to \$28.3 million for the three months ended September 30, 2014. Total interest cost incurred decreased primarily as a result of the exchange of the \$180 million in aggregate principal amount of the operating partnership's Exchangeable Senior Notes due 2030, or the Exchangeable Senior Notes, for shares of common stock during 2014 and January 2015. Interest expense, net decreased \$1.0 million to \$21.2 million for the three months ended September 30, 2015, compared to \$22.2 million for the three months ended September 30, 2014 due to lower interest costs incurred and higher capitalized interest related to increased development in 2015.

Interest expense, net consisted of the following (in thousands):

| | Three Months Ended September 30, | |
|--|-------------------------------------|----------|
| | 2015 | 2014 |
| Mortgage notes payable | \$6,181 | \$6,156 |
| Amortization of debt premium on mortgage notes payable | (554) | (665) |
| Amortization of deferred interest costs | 1,647 | 1,677 |
| Derivative instruments | 828 | 895 |
| Unsecured senior term loans | 1,747 | 1,785 |
| Exchangeable senior notes | — | 1,241 |
| Unsecured senior notes | 12,957 | 12,959 |
| Amortization of debt discount on notes | 363 | 326 |
| Unsecured line of credit | 2,479 | 1,793 |
| Unsecured line of credit fees | 460 | 460 |
| Amortization of deferred loan fees | 1,160 | 1,451 |
| Amortization - put / call / preferred return | 646 | 256 |
| Interest cost incurred | 27,914 | 28,334 |
| Capitalized interest | (6,686) | (6,119) |
| Total interest expense, net | \$21,228 | \$22,215 |

Gain on sale of real estate. Gain on sale of real estate of \$1.9 million for the three months ended September 30, 2015 related to the sale of the 65 West Watkins Mill Road property for \$7.9 million in gross proceeds in September 2015.

Other Income, net. Other income of \$18.8 million for the three months ended September 30, 2015 was due to a \$19.5 million gain from the sale of our investments in certain publicly-traded companies, partially offset by an income tax expense of \$685,000. Other income of \$2.1 million for the three months ended September 30, 2014 was primarily due to a \$2.3 million increase in the value of our investment in a privately-held company which completed a capital transaction during the quarter, and \$681,000 in dividend income relating to investment securities, partially offset by an income tax expense of \$538,000.

Comparison of the Nine Months Ended September 30, 2015 to the Nine Months Ended September 30, 2014

The following table sets forth historical financial information of the operations for same properties (all properties except properties held for sale, previous same properties, development properties, new properties and other entities), previous same properties (properties previously included in the same property portfolio during the nine months ended September 30, 2014 that are now in the land bank), development properties (properties that were entirely or primarily under active new construction during either of the nine months ended September 30, 2015 or 2014), new properties (properties that were not owned for each of the nine months ended September 30, 2015 and 2014 and were not previous same properties or development properties) and other entities (legal entities performing corporate level functions and properties that were sold during or in between the comparative periods (dollars in thousands, except on a per square foot basis):

Table of Contents

| | For the Nine Months Ended September 30, 2015 | | | | | | | | | |
|--------------------------------------|---|----------------------|------------|-------------|-------------------|-----------|------------|---|--|--|
| | Same Properties | Previous Same (1) | Total | Development | New Properties | Other (2) | Total | | | |
| Rentable square feet | 14,363,890 | — | 14,363,890 | 3,460,866 | 687,944 | N/A | 18,512,700 | | | |
| Percent of total portfolio | 77.6 | % — | % 77.6 | % 18.7 | % 3.7 | % N/A | 100.0 | % | | |
| Percent leased | 92.6 | % — | % 92.6 | % 78.9 | % 98.8 | % N/A | 90.2 | % | | |
| | For the Nine Months Ended September 30, 2015 | | | | | | | | | |
| | Same Properties | Previous Same (1) | Total | Development | New Properties | Other (2) | Total | | | |
| Rental revenue | \$328,855 | \$122 | \$328,977 | \$16,189 | 11,994 | \$(48) | \$357,112 | | | |
| Tenant recoveries | 122,620 | (69) | 122,551 | 2,823 | 6,978 | 716 | 133,068 | | | |
| Other revenue (3) | — | — | — | — | — | 20,152 | 20,152 | | | |
| Total revenues | 451,475 | 53 | 451,528 | 19,012 | 18,972 | 20,820 | 510,332 | | | |
| Rental operations | 154,047 | 218 | 154,265 | 8,010 | 7,678 | 6,033 | 175,986 | | | |
| Net operating income / (loss) | 297,428 | (165) | 297,263 | 11,002 | 11,294 | 14,787 | 334,346 | | | |
| Adjustments to cash basis (4) | (7,389) | \$— | (7,389) | (5,160) | (948) | 441 | (13,056) | | | |
| Net operating income - cash basis | \$290,039 | \$(165) | \$289,874 | \$5,842 | \$10,346 | \$15,228 | \$321,290 | | | |
| Rental revenue - cash basis (5) | \$316,522 | \$122 | \$316,644 | \$10,533 | \$11,046 | \$33 | \$338,256 | | | |
| | For the Nine Months Ended 9/30/2014 | | | | | | | | | |
| | Same Properties | Previous Same (1) | Total | Development | New Properties | Other (2) | Total | | | |
| Rentable square feet | 14,363,890 | 107,231 | 14,471,121 | 1,514,703 | 518,940 | N/A | 16,504,764 | | | |
| Percent of total portfolio | 87.1 | % 0.6 | % 87.7 | % 9.2 | % 3.1 | % N/A | 100.0 | % | | |
| Percent leased | 90.4 | % 71.0 | % 90.4 | % 84.9 | % 98.7 | % N/A | 90.3% | | | |
| | For the Nine Months Ended September 30, 2014 | | | | | | | | | |
| | Same Properties | Previous Same | Total | Development | New Properties | Other (2) | Total | | | |
| Rental revenue | \$332,922 | \$2,416 | \$335,338 | \$2,844 | 5,400 | \$20,206 | \$363,788 | | | |
| Tenant recoveries | 115,263 | 640 | 115,903 | 202 | 3,842 | 1,694 | 121,641 | | | |
| Other revenue (3) | — | — | — | — | — | 23,524 | 23,524 | | | |
| Total revenues | 448,185 | 3,056 | 451,241 | 3,046 | 9,242 | 45,424 | 508,953 | | | |
| Rental operations | 145,184 | 1,506 | 146,690 | 2,098 | 4,373 | 7,897 | 161,058 | | | |
| Net operating income | 303,001 | 1,550 | 304,551 | 948 | 4,869 | 37,527 | 347,895 | | | |
| Adjustments to cash basis (4) | (4,707) | \$1,865 | (2,842) | (313) | (261) | (685) | (4,101) | | | |
| Net operating income - cash basis | \$298,294 | \$3,415 | \$301,709 | \$635 | \$4,608 | \$36,842 | \$343,794 | | | |
| Rental revenue - cash basis (5) | \$324,124 | \$4,281 | \$328,405 | \$2,049 | \$5,139 | \$19,522 | \$355,115 | | | |

- (1) Properties previously included in the same property portfolio during the nine months ended September 30, 2014 that are now in the land bank include our 700 and 750 Gateway properties.

Other includes legal entities performing corporate level functions and properties that were sold during, or in between the comparative periods, which includes revenue and operating expenses relating to the 65 West Watkins Mill Road property, which was sold on September 24, 2015, and the 9911 Belward Campus Drive property, which was sold on December 9, 2014, and the King of Prussia property, which was sold on May 29, 2015.

(2) During the nine months ended September 30, 2015 and 2014, we recorded lease termination revenue of approximately \$19.3 million and \$9.8 million, respectively. Lease termination revenue for the nine months ended September 30, 2015 primarily related to the early termination of Vertex Pharmaceuticals' leases at three of our properties in Cambridge, Massachusetts. Lease termination revenue for the nine months ended September 30, 2014 primarily related to the early termination of leases

Table of Contents

at our 4570 Executive Drive property. During the nine months ended September 30, 2014, we also recorded a prepayment fee of approximately \$7.5 million, net of deferred loan fees write-offs, and \$3.9 million of interest income related to the investment in our Construction Loan, which was fully repaid in May 2014 prior to maturity.

Adjustments to cash basis exclude adjustments to expenses accrued in rental operations, but include straight line (4) rents, fair-value lease revenue, lease incentive revenue, bad debt expense and rental cash receipts deferred for GAAP purposes.

(5) Rental revenues - cash basis calculated by adjusting for straight-line rents, lease incentives, fair value lease revenue and rental cash receipts deferred for GAAP purposes.

The following table provides a reconciliation of net operating income - cash basis to net income for the nine months ended September 30, 2015 and 2014 (in thousands):

| | Nine Months Ended | | | Percent | |
|---|-----------------------|-----------|------------|---------|----|
| | September 30, 2015 | 2014 | Change | Change | |
| Net operating income - cash basis | \$321,290 | \$343,794 | \$(22,504) | (6.5) |)% |
| Adjustments to cash basis | 13,056 | 4,101 | 8,955 | 218.4 | % |
| Net operating income | 334,346 | 347,895 | (13,549) | (3.9) |)% |
| Unallocated expense: | | | | | |
| Depreciation and amortization expense | 193,305 | 189,597 | 3,708 | 2.0 | % |
| General and administrative expense | 38,486 | 37,153 | 1,333 | 3.6 | % |
| Executive severance | 9,891 | — | 9,891 | N/A | |
| Acquisition-related expenses | 2,284 | 2,871 | (587) | (20.4) |)% |
| Income from operations | 90,380 | 118,274 | (27,894) | (23.6) |)% |
| Equity in net income of unconsolidated partnerships | 534 | 585 | (51) | (8.7) |)% |
| Interest expense, net | (61,938) | (73,356) | 11,418 | (15.6) |)% |
| Gain on sale of real estate | 1,869 | — | 1,869 | N/A | |
| Impairment of real estate | (35,071) | — | (35,071) | N/A | |
| Other income, net | 95,675 | 11,338 | 84,337 | 743.8 | % |
| Net income | \$91,449 | \$56,841 | \$34,608 | 60.9 | % |

Net Operating Income. Net operating income decreased \$13.5 million to \$334.3 million for the nine months ended September 30, 2015 compared to \$347.9 million for the nine months ended September 30, 2014. Excluding the impact of lease termination revenue for both periods, the interest income and prepayment fee related to our Construction Loan and the operating results of the 65 West Watkins Mill Road property, which was sold in September 2015 and 9911 Belward Campus Drive property, which was sold in December 2014, net operating income increased by \$9.2 million. This net increase was primarily due to the following:

The acquisition of operating properties totaling 518,940 square feet in 2014 and operating properties totaling 169,000 square feet in the nine months ended September 30, 2015 contributed an additional \$6.4 million in net operating income for the nine months ended September 30, 2015 compared to the nine months ended September 30, 2014;

The placement of properties that were under development into service contributed an increase of \$10.1 million in net operating income for the nine months ended September 30, 2015 compared to the nine months ended September 30, 2014;

The increase was partially offset by a decrease of \$7.3 million in same property and previous same property net operating income for the nine months ended September 30, 2015 compared to the nine months ended September 30, 2014 primarily due to:

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

The early terminations of two tenants occupying a total of 493,366 square feet at four of our properties located in Cambridge, Massachusetts during the nine months ended September 30, 2015; and

The placement of properties that were previously included in the same property portfolio during the nine months ended September 30, 2014 into the land bank during the nine months ended September 30, 2015.

Table of Contents

Depreciation and Amortization Expense. Depreciation and amortization expense increased \$3.7 million to \$193.3 million for the nine months ended September 30, 2015 compared to \$189.6 million for the nine months ended September 30, 2014. The increase was primarily due to the acquisition of operating properties totaling 518,940 square feet with an acquisition date fair-value of \$117.0 million in 2014, the acquisition of two operating properties totaling 169,000 square feet with an acquisition date fair-value of \$100.1 million in 2015 and the placement of four properties totaling 913,349 square feet into service in 2015, partially offset by the sale of our 65 West Watkins Mill Road property in September 2015 and 9911 Belward Campus Drive property in December 2014.

General and Administrative Expenses. General and administrative expenses increased \$1.3 million to \$38.5 million for the nine months ended September 30, 2015 compared to \$37.2 million for the nine months ended September 30, 2014. The increase was primarily due to professional fees incurred in connection with the proposed Mergers with affiliates of Blackstone Real Estate Partners VIII L.P., and higher staffing levels and compensation associated with our above-plan leasing and financial performance, partially offset by higher capitalized payroll related to increased development in 2015 and lower executive compensation due to cessation of employment of one of our executive officers in February 2015.

Executive Severance. Executive severance expense of \$9.9 million for the nine months ended September 30, 2015 related to the cessation of employment of one of our executive officers in February 2015.

Interest Expense, Net. Interest cost incurred for the nine months ended September 30, 2015 totaled \$83.6 million compared to \$89.1 million for the nine months ended September 30, 2014. Total interest cost incurred decreased primarily as a result of the early repayment of the mortgage note secured by our Center for Life Science | Boston property in April 2014 and the exchange of the \$180 million in aggregate principal amount of the Exchangeable Senior Notes for shares of common stock during 2014 and January 2015, partially offset by the issuance of our Notes due 2019 and the assumption of mortgages in our acquisitions of the 300 George Street and 100 College Street properties in April 2014. Interest expense, net decreased \$11.5 million to \$61.9 million for the nine months ended September 30, 2015, compared to \$73.4 million for the nine months ended September 30, 2014 due to lower interest costs incurred and higher capitalized interest related to increased development in 2015.

Interest expense, net consisted of the following (in thousands):

| | Nine Months Ended | |
|--|-------------------|----------|
| | September 30, | |
| | 2015 | 2014 |
| Mortgage notes payable | \$18,694 | \$23,731 |
| Amortization of debt premium on mortgage notes payable | (1,687) | (1,831) |
| Amortization of deferred interest costs | 4,965 | 5,052 |
| Derivative instruments | 2,551 | 2,677 |
| Unsecured senior term loans | 5,105 | 5,572 |
| Exchangeable senior notes | 183 | 4,616 |
| Unsecured senior notes | 38,907 | 35,582 |
| Amortization of debt discount on notes | 1,074 | 858 |
| Unsecured line of credit | 6,054 | 5,981 |
| Unsecured line of credit fees | 1,365 | 1,494 |
| Amortization of deferred loan fees | 3,557 | 4,667 |
| Amortization - put / call / preferred return | 2,827 | 691 |
| Interest cost incurred | 83,595 | 89,090 |
| Capitalized interest | (21,657) | (15,734) |
| Total interest expense, net | \$61,938 | \$73,356 |

Gain on sale of real estate. Gain on sale of real estate of \$1.9 million for the nine months ended September 30, 2015 related to the sale of the 65 West Watkins Mill Road property for \$7.9 million in gross proceeds in September 2015.

Impairment of real estate. Impairment of real estate of \$35.1 million for the nine months ended September 30, 2015 primarily related to our King of Prussia property which was sold in May 2015. The property had been placed under active redevelopment to be held for long-term operations. However, in May 2015, our strategy changed from actively redeveloping to selling with respect to this property as a result of market conditions, which dictated an earlier sale. In connection with the change in strategy in May

Table of Contents

2015, we recognized a non-cash impairment loss of \$32.3 million once the sale of the property became probable and the property was written down to its estimated fair value, less cost to sell. No gain or loss was recorded upon completion of the sale in May 2015. Additionally, we recognized a non-cash impairment loss of \$2.8 million relating to another property that is no longer being developed, which reduced its carrying value to its estimated fair value, less costs to sell.

Other Income, net. Other income of \$95.7 million for the nine months ended September 30, 2015 was primarily due to a \$88.4 million gain from the sale of our investments in certain publicly-traded companies and an \$11.4 million gain related to the collection of a note receivable that was previously fully reserved, partially offset by a \$2.7 million other-than-temporary impairment primarily related to our cost method investments in a privately-held company and a \$1.0 million income tax expense. Other income of \$11.3 million for the nine months ended September 30, 2014 was primarily due to \$12.8 million of gains and dividend income relating to investment securities, partially offset by a \$1.3 million other-than-temporary impairment relating to our cost method investment in a privately-held company.

Cash Flows

Comparison of the Nine Months Ended September 30, 2015 to the Nine Months Ended September 30, 2014

| | Nine Months Ended September 30, | | |
|---|------------------------------------|-----------|------------|
| | 2015 | 2014 | Change |
| | (In thousands) | | |
| Net cash provided by operating activities | \$206,543 | \$223,866 | \$(17,323) |
| Net cash used in investing activities | (403,560) | (270,680) | (132,880) |
| Net cash provided by financing activities | 199,350 | 46,180 | 153,170 |
| Ending cash and cash equivalents balance | 48,675 | 33,864 | 14,811 |

Net cash provided by operating activities decreased \$17.3 million to \$206.5 million for the nine months ended September 30, 2015 compared to \$223.9 million for the nine months ended September 30, 2014. The decrease primarily resulted from the sale of the 9911 Belward Campus Drive property in December 2014, the early termination of Vertex Pharmaceuticals' leases at three of our properties in Cambridge, Massachusetts in February 2015 and the timing of cash rent commencements on new leases.

Net cash used in investing activities increased \$132.9 million to \$403.6 million for the nine months ended September 30, 2015 compared to \$270.7 million for the nine months ended September 30, 2014. The increase primarily resulted from higher acquisition activities and capital expenditures relating to our development projects during the nine months ended September 30, 2015 compared to the nine months ended September 30, 2014, net of tax credit contributions received. The increase was partially offset by the decrease in draws on our notes receivable and Construction Loan, which was repaid in May 2014, cash proceeds from the sales of our King of Prussia and 65 West Watkins Mill Road properties in May 2015 and September 2015, respectively, and proceeds from sales of marketable securities during the nine months ended September 30, 2015.

For the nine months ended September 30, 2015, net cash provided by financing activities was \$199.4 million compared to \$46.2 million for the nine months ended September 30, 2014. Net cash provided by financing activities of \$199.4 million during the nine months ended September 30, 2015 primarily resulted from a net draw on our line of credit, partially offset by dividends paid to common stockholders and distributions to noncontrolling interests. Net cash provided by financing activities of \$46.2 million during the nine months ended September 30, 2014 primarily resulted from proceeds from the issuance of our Notes due 2019 and a net draw on our line of credit, partially offset by the early repayment of the mortgage note secured by our Center for Life Science | Boston property and payment of dividends to common stockholders and distributions to noncontrolling interests.

Funds from Operations

We present funds from operations, or FFO, and FFO excluding acquisition-related expenses, or CFFO, attributable to common shares and OP units because we consider them to be important supplemental measures of our operating performance and believe they are frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO and CFFO when reporting their results. FFO and CFFO are intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO and CFFO exclude depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, and, in the case of CFFO, acquisition-related expenses, they provide performance measures that, when compared year over year, reflect the impact

Table of Contents

to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT. As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of depreciable property, impairment charges on depreciable real estate, real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures. Our computations may differ from the methodologies for calculating FFO and CFFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO and CFFO do not represent amounts available for management's discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO and CFFO should not be considered alternatives to net income / (loss) (computed in accordance with GAAP) as indicators of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as indicators of our liquidity, nor are they indicative of funds available to fund our cash needs, including our ability to pay dividends or make distributions. Our FFO and CFFO attributable to common shares and OP units and a reconciliation to net income for the three and nine months ended September 30, 2015 and 2014 (in thousands, except per share and share data) were as follows:

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|-------------|------------------------------------|-------------|
| | 2015 | 2014 | 2015 | 2014 |
| Net income attributable to the Company | \$28,203 | \$15,960 | \$69,126 | \$53,429 |
| Adjustments: | | | | |
| Gain on sale of real estate | (1,869) |) — | (1,869) |) — |
| Impairment of real estate | — | — | 35,071 | — |
| Noncontrolling interests in operating partnership (1) | 734 | 429 | 1,804 | 1,464 |
| Depreciation and amortization - unconsolidated partnerships | 471 | 2,312 | 2,527 | 3,088 |
| Depreciation and amortization - consolidated entities | 64,953 | 64,452 | 193,305 | 189,597 |
| Depreciation and amortization - allocable to noncontrolling interest of consolidated joint ventures | (593) |) (699) |) (2,178) |) (1,739) |
| FFO attributable to common shares and units - basic | 91,899 | 82,454 | 297,786 | 245,839 |
| Interest expense on Exchangeable Senior Notes (2) | — | 1,241 | 183 | 4,616 |
| FFO attributable to common shares and units - diluted | 91,899 | 83,695 | 297,969 | 250,455 |
| Acquisition-related expenses | 720 | 487 | 2,284 | 2,871 |
| CFFO attributable to common shares and units - diluted | \$92,619 | \$84,182 | \$300,253 | \$253,326 |
| FFO per share - diluted | \$0.44 | \$0.40 | \$1.42 | \$1.20 |
| CFFO per share - diluted | \$0.44 | \$0.40 | \$1.44 | \$1.21 |
| Weighted-average common shares and units outstanding - diluted (2) (3) | 209,144,827 | 208,649,141 | 209,115,535 | 208,723,924 |

Net income attributable to noncontrolling interests in the operating partnership is included in net income (1) attributable to unit holders of the operating partnership as reflected in the consolidated financial statements of our operating partnership, included elsewhere herein.

Reflects interest expense adjustment of the Exchangeable Senior Notes based on the "if converted" method. The nine months ended September 30, 2015 and the three and nine months ended September 30, 2014 include 393,631, (2) 7,589,600 and 9,571,008 shares of common stock, respectively, potentially issuable pursuant to the exchange feature of the Exchangeable Senior Notes based on the "if converted" method.

(3) The three months ended September 30, 2015 and 2014 include 1,343,243 and 1,484,648 shares of unvested restricted stock, respectively, which are considered anti-dilutive for purposes of calculating diluted earnings per

share. The nine months ended September 30, 2015 and 2014 include 1,396,350 and 1,501,559 shares of unvested restricted stock, respectively, which are considered anti-dilutive for purposes of calculating diluted earnings per share.

Liquidity and Capital Resources of BioMed Realty Trust, Inc.

In this “Liquidity and Capital Resources of BioMed Realty Trust, Inc.” section, the term the “Company” refers only to BioMed Realty Trust, Inc. on an unconsolidated basis, and excludes the operating partnership and all other subsidiaries. For further discussion

Table of Contents

of the liquidity and capital resources of the Company on a consolidated basis, see the section entitled “Liquidity and Capital Resources of BioMed Realty, L.P.” below.

As discussed in Note 12 of the Notes to Consolidated Financial Statements included elsewhere herein, the Merger Agreement contains provisions which restrict or prohibit certain capital expenditures as well as certain capital transactions typically used to fund the Company’s and the operating partnership’s short and long-term liquidity requirements. Until the Mergers close, or the Merger Agreement is terminated, the Company’s and the operating partnership’s liquidity requirements will primarily be funded with net cash provided by operating activities and certain other capital activities allowed under the Merger Agreement. In particular, the Company and the operating partnership are subject to various restrictions under the Merger Agreement on raising additional capital, issuing additional equity or debt, repurchasing equity or debt, and entering into certain acquisition, disposition and leasing transactions, among other restrictions.

The Company’s business is operated primarily through the operating partnership. The Company issues public equity from time to time, but does not otherwise generate any capital itself or conduct any business itself, other than incurring certain expenses in operating as a public company which are fully reimbursed by the operating partnership. The Company itself does not hold any indebtedness, and its only material asset is its ownership of partnership interests of the operating partnership. The Company’s principal funding requirement is the payment of dividends on its common stock. The Company’s principal source of funding for its dividend payments is distributions it receives from the operating partnership.

As of September 30, 2015, the Company owned an approximate 97.5% partnership interest and other limited partners, including some of our directors, executive officers and their affiliates, owned the remaining 2.5% partnership interest (including LTIP units) in the operating partnership. As the sole general partner of the operating partnership, BioMed Realty Trust, Inc. has the full, exclusive and complete responsibility for the operating partnership’s day-to-day management and control.

The liquidity of the Company is dependent on the operating partnership’s ability to make sufficient distributions to the Company. The primary cash requirement of the Company is its payment of dividends to its stockholders; under the terms of the Merger Agreement, the Company was permitted to pay one additional common stock dividend of \$0.26 per share on October 15, 2015, but will not be permitted to pay common stock dividends for any quarter thereafter, subject to certain exceptions. The Company also guarantees some of the operating partnership’s debt, as discussed further in Note 5 of the Notes to Consolidated Financial Statements included elsewhere herein. If the operating partnership fails to fulfill certain of its debt requirements, which trigger the Company’s guarantee obligations, then the Company will be required to fulfill its cash payment commitments under such guarantees. However, the Company’s only significant asset is its investment in the operating partnership.

We believe the operating partnership’s sources of working capital, specifically its cash flow from operations, and borrowings available under its unsecured line of credit, are adequate for it to make its distribution payments to the Company and, in turn, for the Company to make its dividend payments to its stockholders (subject to the restrictions under the Merger Agreement described above). However, we cannot assure you that the operating partnership’s sources of capital will continue to be available at all or in amounts sufficient to meet its needs, including its ability to make distribution payments to the Company. The unavailability of capital could adversely affect the operating partnership’s ability to pay its distributions to the Company, which would in turn, adversely affect the Company’s ability to pay cash dividends to its stockholders.

Our short-term liquidity requirements consist primarily of funds to pay for future dividends expected to be paid to the Company’s stockholders, operating expenses and other expenditures directly associated with our properties, interest expense and scheduled principal payments on outstanding indebtedness, general and administrative expenses, construction projects, capital expenditures, tenant improvements and leasing commissions.

The Company may, subject to the restrictions under the Merger Agreement, from time to time seek to repurchase or redeem the operating partnership’s outstanding debt, the Company’s shares of common stock or other securities in open market purchases, privately negotiated transactions or otherwise. Such repurchases or redemptions, if any, will depend

on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

For the Company to maintain its qualification as a REIT, it must pay dividends to its stockholders aggregating annually at least 90% of its REIT taxable income, excluding net capital gains. While historically the Company has satisfied this distribution requirement by making cash distributions to its stockholders, it may choose to satisfy this requirement by making distributions of cash or other property, including, in limited circumstances, the Company's own stock. As a result of this distribution requirement, the operating partnership cannot rely on retained earnings to fund its ongoing operations to the same extent that other companies whose parent companies are not REITs can. The Company may need to continue to raise capital in the equity markets to fund the operating partnership's working capital needs, acquisitions and developments, subject to the restrictions under the Merger Agreement.

Table of Contents

The Company is a well-known seasoned issuer with an effective shelf registration statement that allows the Company to register an unspecified amount of various classes of equity securities and the operating partnership to register an unspecified amount of various classes of debt securities. As circumstances warrant, the Company may, subject to the restrictions under the Merger Agreement, issue equity from time to time on an opportunistic basis, dependent upon market conditions and available pricing. When the Company receives proceeds from preferred or common equity issuances, it is required by the operating partnership's partnership agreement to contribute the proceeds from its equity issuances to the operating partnership in exchange for preferred or common partnership units of the operating partnership. The operating partnership may use the proceeds to repay debt, to develop new or existing properties, to acquire properties or for general corporate purposes.

See the discussion above and in Note 12 of the Notes to Consolidated Financial Statements included elsewhere herein regarding restrictions under the Merger Agreement to which the Company is subject.

Liquidity and Capital Resources of BioMed Realty, L.P.

In this "Liquidity and Capital Resources of BioMed Realty, L.P." section, the terms "we," "our" and "us" refer to the operating partnership together with its consolidated subsidiaries or the operating partnership and BioMed Realty Trust, Inc. together with their consolidated subsidiaries, as the context requires. BioMed Realty Trust, Inc., or our Parent Company, is our sole general partner and consolidates our results of operations for financial reporting purposes.

Because we operate on a consolidated basis with our Parent Company, the section entitled "Liquidity and Capital Resources of BioMed Realty Trust, Inc." should be read in conjunction with this section to understand our liquidity and capital resources on a consolidated basis.

Our short-term liquidity requirements consist primarily of funds to pay for future dividends expected to be paid to our Parent Company's stockholders, operating expenses and other expenditures directly associated with our properties, interest expense and scheduled principal payments on outstanding indebtedness, general and administrative expenses, construction projects, capital expenditures, tenant improvements and leasing commissions.

The remaining principal payments due for our consolidated and our proportionate share of unconsolidated indebtedness (excluding debt premiums and discounts) as of September 30, 2015 were as follows (in thousands):

Table of Contents

| | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | Thereafter | Total |
|--|---------|-----------|-----------|-----------|-----------|-----------|------------|-------------|
| Consolidated indebtedness: | | | | | | | | |
| Principal Amortization | \$2,620 | \$13,560 | \$9,796 | \$9,852 | \$5,724 | \$6,139 | \$29,332 | \$77,023 |
| Maturity Payments | — | 263,073 | 22,510 | 37,952 | — | — | 80,330 | \$403,865 |
| Total mortgage notes payable | 2,620 | 276,633 | 32,306 | 47,804 | 5,724 | 6,139 | 109,662 | 480,888 |
| Unsecured line of credit | — | — | — | 463,000 | — | — | — | 463,000 |
| Term Loan due 2017 - U.S. dollar | — | — | 243,596 | — | — | — | — | 243,596 |
| Term Loan due 2017 - GBP (1) | — | — | 151,530 | — | — | — | — | 151,530 |
| Term Loan due 2018 | — | — | — | 350,000 | — | — | — | 350,000 |
| Notes due 2016 | — | 400,000 | — | — | — | — | — | 400,000 |
| Notes due 2019 | — | — | — | — | 400,000 | — | — | 400,000 |
| Notes due 2020 | — | — | — | — | — | 250,000 | — | 250,000 |
| Notes due 2022 | — | — | — | — | — | — | 250,000 | 250,000 |
| Total consolidated indebtedness | 2,620 | 676,633 | 427,432 | 860,804 | 405,724 | 256,139 | 359,662 | 2,989,014 |
| Share of unconsolidated indebtedness: | | | | | | | | |
| Secured mortgage | — | — | 1,431 | — | — | — | — | 1,431 |
| Secured construction loan (2) | — | — | — | — | — | 32,000 | — | 32,000 |
| Total share of unconsolidated indebtedness | — | — | 1,431 | — | — | 32,000 | — | 33,431 |
| Total indebtedness | \$2,620 | \$676,633 | \$428,863 | \$860,804 | \$405,724 | \$288,139 | \$359,662 | \$3,022,445 |

(1) The principal balance represents the U.S. dollar amount based on the exchange rate of \$1.52 to £1.00 at September 30, 2015.

In July 2015, a wholly-owned subsidiary of PREI I LLC refinanced its secured loan facility with previously outstanding borrowings of \$139.0 million into a new secured loan with a principal amount of \$160.0 million, an (2) interest rate equal to LIBOR plus 140 basis points, and a maturity date of August 1, 2020 (with two options to extend the maturity date for one year each at its discretion after satisfying certain conditions and paying an extension fee).

Certain of our mortgage loans include financial covenants which require us to maintain minimum levels of debt service coverage and a minimum amount of net worth. Management believes that we were in compliance with these covenants as of September 30, 2015.

During the nine months ended September 30, 2015, at the request of the holders that exercised their exchange right pursuant to the terms of the Exchangeable Senior Notes, our Parent Company issued 5,764,026 shares of its common stock in exchange for the remaining \$95.7 million in aggregate principal amount of the Exchangeable Senior Notes. During the nine months ended September 30, 2015, we received \$90.4 million in proceeds from sales of investments in publicly-traded companies, resulting in a realized gain on sale of \$68.6 million, net of allocation to a noncontrolling interest.

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

In May 2015, we sold our King of Prussia property for \$35.0 million, excluding closing costs, and incurred a non-cash impairment charge of \$32.3 million in the second quarter of 2015 as a result of the sale.

On June 30, 2015, we repaid in full the mortgage loan of \$21.0 million, secured by our 4320 Forest Park Avenue property at its scheduled maturity date, which bore interest at a fixed rate of 4.0% per annum.

The credit facilities governing our unsecured line of credit, Term Loan due 2017 and Term Loan due 2018 include certain restrictions and covenants relating to, among other things, overall leverage and unsecured leverage ratios, fixed charge coverage,

Table of Contents

unsecured debt service coverage, maximum amount of secured indebtedness and certain investment limitations.

Management believes that we were in compliance with these covenants as of September 30, 2015.

The terms of the indentures governing the Notes due 2016, the Notes due 2019, the Notes due 2020 and the Notes due 2022 require compliance with various financial covenants, including limits on the amount of total leverage and secured debt maintained by us and which require us to maintain minimum levels of debt service coverage.

Management believes that we were in compliance with these covenants as of September 30, 2015.

Our long-term liquidity requirements consist primarily of funds to pay for scheduled debt maturities, construction obligations, renovations, expansions, capital commitments and other non-recurring capital expenditures that need to be made periodically, and the costs associated with acquisitions of properties that we pursue. At September 30, 2015, we had entered into construction contracts and lease agreements, with a remaining commitment totaling approximately \$806.3 million related to tenant improvements, leasing commissions and construction-related capital expenditures.

We expect to satisfy our short-term liquidity requirements through our existing working capital and cash provided by our operations, the issuance of long-term secured and unsecured indebtedness, the issuance of additional equity or debt securities and the use of net proceeds from the disposition of non-strategic assets (subject to the restrictions under the Merger Agreement, discussed above and in Note 12 of the Notes to Consolidated Financial Statements included elsewhere herein). Our rental revenues, provided by our leases, generally provide cash inflows to meet our debt service obligations, pay general and administrative expenses, and fund regular distributions. We expect to satisfy our long-term liquidity requirements through our existing working capital, cash provided by operations, long-term secured and unsecured indebtedness and the issuance of additional equity or debt securities (subject to the restrictions under the Merger Agreement). We also expect to use funds available under our unsecured line of credit to finance acquisition and development activities and capital expenditures on an interim basis (subject to the restrictions under the Merger Agreement). We also expect to utilize tax credits, grants and other subsidies from time to time to fund development activities. In addition, we have an investment grade credit rating, which we believe will provide us with continued access to the unsecured debt markets, providing us with an additional source of long term financing (subject to the restrictions under the Merger Agreement).

BioMed Realty Trust, Inc.'s total capitalization at September 30, 2015 was approximately \$7.2 billion and was comprised of the following (dollars in thousands):

| | Shares/Units at September 30, 2015 | Aggregate Principal Amount or Dollar Value Equivalent | Percent of Total Capitalization | |
|---|--|---|------------------------------------|---|
| Debt: | | | | |
| Mortgage notes payable (1) | | \$480,888 | 6.7 | % |
| Unsecured senior notes (1) | | 1,300,000 | 18.1 | % |
| Unsecured senior term loans (2) | | 745,126 | 10.4 | % |
| Unsecured line of credit | | 463,000 | 6.5 | % |
| Total debt | | 2,989,014 | 41.7 | % |
| Equity: | | | | |
| Common shares, operating partnership and LTIP units outstanding (3) | 208,926,011 | 4,174,341 | 58.3 | % |
| Total equity | | 4,174,341 | 58.3 | % |
| Total capitalization | | \$7,163,355 | 100.0 | % |

(1) Amounts exclude unamortized debt premiums and unamortized debt discounts.

(2) In August 2012, the operating partnership converted approximately \$156.4 million of outstanding borrowings of the Term Loan due 2017 into British pounds sterling ("GBP") equal to £100.0 million, which was designated as a net investment hedge to mitigate the risk of fluctuations in foreign currency exchange rates. \$151.5 million of the

principal balance represents the U.S. dollar amount based on the exchange rate of \$1.52 to £1.00 at September 30, 2015.

(3) Aggregate amount based on the market closing price of the common stock of our Parent Company of \$19.98 per share on the last trading day of the quarter. Limited partners who have been issued OP units have the right to require the operating partnership to redeem part or all of their OP units, which right with respect to LTIP units is subject to vesting and the satisfaction of other conditions. We may elect to redeem those OP units in exchange for shares of our Parent Company's common stock on a one-for-one basis, subject to adjustment. At September 30, 2015, 203,527,787 of the outstanding OP units had been issued to our

Table of Contents

Parent Company upon receipt of the net proceeds from the issuance of an equal number of shares of our Parent Company's common stock.

Our organizational documents do not limit the amount of indebtedness that we may incur, and we may modify our financing strategy from time to time in light of current economic or market conditions including, but not limited to, the relative costs of debt and equity capital, market conditions for debt and equity securities and fluctuations in the market price of our Parent Company's common stock (subject to the restrictions under the Merger Agreement). In addition, the terms of the indentures governing our Notes due 2016, Notes due 2019, Notes due 2020 and Notes due 2022, and the credit facilities governing our unsecured line of credit, Term Loan due 2017 and Term Loan due 2018 require compliance with various financial covenants and ratios, which are discussed in detail above and in Note 5 of the Notes to Consolidated Financial Statements contained elsewhere herein.

We may from time to time seek to repurchase or redeem our outstanding debt or OP units (including in connection with the repurchase or redemption of an equivalent number of shares of common stock by our Parent Company) or other securities, and our Parent Company may seek to repurchase or redeem its outstanding shares of common stock or other securities, in each case in open market purchases, privately negotiated transactions or otherwise (subject to the restrictions under the Merger Agreement). Such repurchases or redemptions, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

Off-Balance Sheet Arrangements

As of September 30, 2015, we had investments in the following unconsolidated partnerships: (1) BioPark Fremont, LLC, which owns a land parcel located in Baltimore; (2) McKellar Court limited partnership, which owns a single tenant occupied property located in San Diego; and (3) two limited liability companies with PREI, which own a portfolio of properties located in Cambridge, Massachusetts (see Note 8 of the Notes to Consolidated Financial Statements included elsewhere herein for more information).

BioPark Fremont, LLC is a VIE; however, we are not the primary beneficiary. We will receive 50% of the operating cash flows and 50% of the gains upon sale of the property. We account for our membership interest using the equity method. The assets of BioPark Fremont, LLC were \$3.3 million and \$3.1 million at September 30, 2015 and December 31, 2014, respectively. The liabilities of BioPark Fremont, LLC were \$2.9 million at each of September 30, 2015 and December 31, 2014. Our equity in net loss of BioPark Fremont, LLC was \$147,000 and \$39,000 for the nine months ended September 30, 2015 and 2014, respectively.

The McKellar Court partnership is a VIE; however, we are not the primary beneficiary. The limited partner at McKellar Court is the only tenant in the property and will bear a disproportionate amount of any losses. We, as the general partner, will receive 22% of the operating cash flows and 75% of the gains upon sale of the property. We account for our general partner interest using the equity method. The assets of the McKellar Court partnership were \$13.0 million and \$13.4 million at September 30, 2015 and December 31, 2014, respectively. The liabilities were \$10.8 million and \$10.7 million at September 30, 2015 and December 31, 2014, respectively. Our equity in net income of the McKellar Court partnership was \$724,000 and \$686,000 for the nine months ended September 30, 2015 and 2014, respectively. In December 2009, we provided funding in the form of a promissory note to the McKellar Court partnership in the amount of \$10.3 million, which matures at the earlier of (1) January 1, 2020, or (2) the day that the limited partner exercises an option to purchase our ownership interest. Interest-only payments on the promissory note are due monthly at a fixed rate of 8.15%, with the principal balance outstanding due at maturity.

PREI II LLC is a VIE; however, we are not the primary beneficiary. PREI will bear the majority of any losses incurred. PREI I LLC does not qualify as a VIE. In addition, consolidation is not required as we do not control the limited liability companies. In connection with the formation of the PREI joint ventures in April 2007, we contributed 20% of the initial capital. However, the amount of cash flow distributions that we receive may be more or less based on the nature of the circumstances underlying the cash distributions due to provisions in the operating agreements governing the distribution of funds to each member and the occurrence of extraordinary cash flow events. We account for our member interests using the equity method for both limited liability companies. The assets of the PREI joint ventures were \$267.7 million and \$268.2 million at September 30, 2015 and December 31, 2014, respectively, and the

liabilities were \$178.7 million and \$147.5 million at September 30, 2015 and December 31, 2014, respectively. Our equity in net loss of the PREI joint ventures was \$43,000 and \$62,000 for the nine months ended September 30, 2015 and 2014, respectively.

We are the primary beneficiary in VIEs at the following properties in which a tenant has a purchase option, which are consolidated and reflected in our consolidated financial statements (in thousands):

53

Table of Contents

| Property | Earliest Purchase Option Exercise Price | Net Book Value September 30, 2015 | Projected Net Book Value at Earliest Purchase Option Exercise Date | Earliest Purchase Option Exercise Date |
|--------------------------|---|--------------------------------------|--|--|
| Shady Grove Road | \$302,800 | \$185,851 | \$185,851 | Any time before December 1, 2015 |
| 300 George Street (1) | 127,750 | 110,583 | 99,846 | December 31, 2017 |
| Nancy Ridge (2) | 105,853 | 71,999 | 69,483 | May 2, 2017 |
| South Street Landing (3) | 116,312 | 33,387 | 78,527 | June 30, 2022 |
| Other (4) | 155,325 | 150,520 | 125,948 | Various |
| Total | \$808,040 | \$552,340 | \$559,655 | |

Purchase option can be exercised on December 31 of each year beginning 2017 through 2031 and on April 30, (1)2032 with the purchase option exercise price ranging from \$127.8 million to \$159.7 million, plus adjustments for capital expenditures.

Includes 6114 - 6154 Nancy Ridge Drive and 6122 - 6126 Nancy Ridge Drive. Purchase option can be exercised (2) on May 2 of 2017, 2022 and 2027, as well as upon transfer of control. The purchase option exercise price is determined based on a 7.9% capitalization rate on annualized monthly rent at exercise.

Includes purchase options by two tenants for their respective units. The purchase options can be exercised during (3) the sixth year and after the twelfth year of the leases and may also be extended upon exercise of a renewal option. The purchase option exercise price is based on fair-market value at exercise with a combined floor price estimated at \$116.3 million based on the total projected costs to develop the property, net of expected tax subsidies.

Includes 1701 / 1711 Research Boulevard, Gazelle Court, Faraday Avenue and a portion of Wake 60. The purchase (4) options can be exercised at various times between 2016 and 2033 based on fixed-prices, pre-determined internal rate of returns or fair-market value at exercise.

At September 30, 2015 and December 31, 2014, we were also the primary beneficiary of VIEs at eleven and ten properties with tax credit structures, respectively, which are consolidated and reflected in our consolidated financial statements.

Our proportionate share of outstanding debt related to our unconsolidated partnerships is summarized below (dollars in thousands):

| Name | Ownership Percentage | Interest Rate(2) | Principal Amount(1) | | Maturity Date |
|-----------------|----------------------|------------------|---------------------|-------------------|----------------|
| | | | September 30, 2015 | December 31, 2014 | |
| BioPark Fremont | 50 | % 2.7 | % \$1,431 | \$1,401 | May 1, 2017 |
| PREI I LLC (3) | 20 | % 3.1 | % 32,000 | 27,795 | August 1, 2020 |
| Total | | | \$33,431 | \$29,196 | |

(1) Amount represents our proportionate share of the total outstanding indebtedness for each of the unconsolidated partnerships.

(2) Effective or weighted-average interest rate of the outstanding indebtedness as of September 30, 2015.

Amount represents our proportionate share of a secured loan executed by a wholly-owned subsidiary of PREI I LLC with a principal amount of \$160.0 million, an interest rate equal to LIBOR plus 140 basis points, and a (3) maturity date of August 1, 2020 (with two options to extend the maturity date for one year each at its discretion after satisfying certain conditions and paying an extension fee).

Cash Distribution Policy

We elected to be taxed as a REIT under the Internal Revenue Code of 1986, as amended, or the Code, commencing with our taxable year ended December 31, 2004. To qualify as a REIT, we must meet a number of organizational and operational requirements, including the requirement that we distribute currently at least 90% of our ordinary taxable income to our stockholders. It is our intention to comply with these requirements and maintain our REIT status. As a REIT, we generally will not be subject to U.S. corporate federal, state or local income taxes on taxable income we distribute currently (in accordance with the Code and applicable regulations) to our stockholders. If we fail to qualify as a REIT in any taxable year, we will be subject to U.S. federal, state and local income taxes at regular corporate rates and may not be able to qualify as a REIT for subsequent tax years. Even if we qualify as a REIT for federal income tax purposes, we may be subject to certain foreign, state and local taxes on our income and to federal

Table of Contents

income and excise taxes on our undistributed taxable income, i.e., taxable income not distributed in the amounts and in the time frames prescribed by the Code and applicable regulations thereunder.

While we most recently paid a dividend on shares of common stock at an annual dividend rate of \$1.04 per share, the actual dividend payable in the future will be determined by our board of directors based upon the circumstances at the time of declaration and, as a result, the actual dividend payable in the future may vary from the current rate. The decision to declare and pay dividends on shares of our common stock in the future, as well as the timing, amount and composition of any such future dividends, will be at the sole discretion of our board of directors in light of conditions then existing, including our earnings, financial condition, capital requirements, debt maturities, the availability of debt and equity capital, applicable REIT and legal restrictions and general overall economic conditions and other factors (including being subject to the restrictions under the Merger Agreement).

The following table provides historical dividend information for our common stock for the prior two fiscal years and the nine months ended September 30, 2015, excluding a special dividend of \$0.30 per share declared and paid during the fourth quarter 2014, reflecting a return to stockholders of a portion of the proceeds from the sale of our 9911 Belward Campus Drive property:

| Quarter Ended | Date Declared | Date Paid | Dividend per Common Share |
|--------------------|--------------------|------------------|------------------------------|
| March 31, 2013 | March 15, 2013 | April 15, 2013 | \$0.235 |
| June 30, 2013 | June 14, 2013 | July 15, 2013 | 0.235 |
| September 30, 2013 | September 16, 2013 | October 15, 2013 | 0.235 |
| December 31, 2013 | December 12, 2013 | January 15, 2014 | 0.250 |
| March 31, 2014 | March 17, 2014 | April 15, 2014 | 0.250 |
| June 30, 2014 | June 16, 2014 | July 15, 2014 | 0.250 |
| September 30, 2014 | September 16, 2014 | October 15, 2014 | 0.250 |
| December 31, 2014 | December 15, 2014 | January 15, 2015 | 0.260 |
| March 31, 2015 | March 16, 2015 | April 15, 2015 | 0.260 |
| June 30, 2015 | June 15, 2015 | July 15, 2015 | 0.260 |
| September 30, 2015 | September 15, 2015 | October 15, 2015 | 0.260 |

Inflation

Some of our leases contain provisions designed to mitigate the adverse impact of inflation. These provisions generally increase rental rates during the terms of the leases either at fixed rates or indexed escalations (based on the Consumer Price Index or other measures). We may be adversely impacted by inflation on the leases that do not contain indexed escalation provisions. In addition, most of our leases require the tenant to pay an allocable share of operating expenses, including common area maintenance costs, real estate taxes and insurance. This may reduce our exposure to increases in costs and operating expenses resulting from inflation, assuming our properties remain leased and tenants fulfill their obligations to reimburse us for such expenses.

Our unsecured line of credit, portions of our Term Loan due 2017 and Term Loan due 2018, the outstanding balance of a mortgage secured by a property in Connecticut and our proportionate share of the outstanding balance of the PREI joint ventures' secured construction loan bear interest at variable rates, which will be influenced by changes in short-term interest rates, and will be sensitive to inflation.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our future income, cash flows and fair-values relevant to financial instruments depend upon prevailing market interest rates. Market risk is the exposure to loss resulting from changes in interest rates, foreign currency exchange rates, commodity prices and equity prices. Many factors, including governmental monetary and tax policies, domestic and international economic and political considerations and other factors that are beyond our control contribute to interest

rate risk, equity price risk and foreign currency exchange rate risk.

Interest Rate Risk

As of September 30, 2015, our consolidated debt consisted of the following (dollars in thousands):

55

Table of Contents

| | Principal Balance (1) | Percent of Total Debt | Effective Interest Rate at September 30, 2015 | |
|--|--------------------------|--------------------------|--|---|
| Fixed interest rate (2) | \$1,678,819 | 56.1 | % 4.33 | % |
| Variable interest rate - hedged (3) | 551,530 | 18.4 | % 2.21 | % |
| Variable interest rate - unhedged (4) | 764,820 | 25.5 | % 1.50 | % |
| Total/weighted-average effective interest rate | \$2,995,169 | 100.0 | % 3.22 | % |

(1) Principal balance includes only consolidated indebtedness.

Includes ten mortgage notes payable secured by certain of our properties (including unamortized premiums), our

(2) Notes due 2016 (including unamortized debt discount), our Notes due 2019 (including unamortized debt discount), our Notes due 2020 (including unamortized debt discount) and our Notes due 2022 (including unamortized debt discount).

Includes the hedged portions of our Term Loan due 2017 and Term Loan due 2018, which bear interest at LIBOR-indexed variable interest rates, plus a credit spread. On August 2, 2012, we converted approximately \$156.4 million of outstanding borrowings of the Term Loan due 2017 into GBP equal to £100.0 million. The principal balance represents the U.S. dollar amount based on the exchange rate of \$1.52 to £1.00 at September 30, 2015. The stated effective rate for the variable interest hedged debt includes the impact of our interest rate swap agreements. We have entered into four U.S. dollar interest rate swaps, which are intended to have the effect of initially fixing the interest rate on \$200.0 million of the outstanding amount under our Term Loan due 2017 at a weighted-average interest rate of approximately 2.10% for the remaining term of the Term Loan due 2017

(3) (including applicable credit spreads for the underlying debt), subject to adjustment based on our credit ratings. We have entered into two GBP interest rate swaps, which are intended to have the effect of initially fixing the interest rate on £100.0 million of the outstanding amount under our Term Loan due 2017 at approximately 2.14% for the remaining term of the Term Loan due 2017 (including applicable credit spreads for the underlying debt), subject to adjustment based on our credit ratings. On September 25, 2013, we entered into three U.S. dollar interest rate swaps, which are intended to have the effect of initially fixing the interest rate on \$200.0 million of the outstanding amount under our Term Loan due 2018 at a weighted-average interest rate of approximately 1.28% through October 1, 2016 (including applicable credit spreads for the underlying debt), subject to adjustment based on our credit ratings.

(4) Includes one variable rate mortgage, the unhedged portions of our Term Loan due 2017 and Term Loan due 2018 and our unsecured line of credit, which bear interest at LIBOR-indexed variable interest rates, plus a credit spread. To determine the fair-value of our outstanding consolidated indebtedness, we utilize quoted market prices to estimate the fair-value, when available. If quoted market prices are not available, we calculate the fair-value of our mortgage notes payable and other fixed-rate debt based on an estimate of current lending rates, assuming the debt is outstanding through maturity and considering the notes' collateral. In determining the current market rate for fixed-rate debt, a market credit spread is added to the quoted yields on federal government treasury securities with similar terms to debt. In determining the current market rate for variable-rate debt, a market credit spread is added to the current effective interest rate. At September 30, 2015, both the fair-value and carrying value of all fixed-rate debt was estimated to be \$1.7 billion (including debt premiums and discounts). At September 30, 2015, both the fair-value and carrying value of all variable-rate debt was estimated to be \$1.3 billion. We do not believe that the interest rate risk represented by our fixed-rate debt or the risk of changes in the credit spread related to our variable-rate debt was material as of September 30, 2015 in relation to total assets of \$6.5 billion and equity market capitalization of \$7.2 billion of BioMed Realty Trust, Inc.'s common stock and BioMed Realty, L.P.'s OP units.

Based on the unhedged outstanding balances of our unsecured line of credit, our Term Loan due 2017, our Term Loan due 2018 and our proportionate share of the outstanding balance of the PREI joint ventures' secured construction loan at September 30, 2015, a 1.0% change in interest rates would change our interest costs by approximately \$8.0 million per year. This amount was determined by considering the impact of hypothetical interest rates on our financial

instruments. This analysis does not consider the effect of any change in overall economic activity that could occur in that environment. Further, in the event of a change of the magnitude discussed above, we may take actions to further mitigate our exposure to the change. However, due to the uncertainty of the specific actions that would be taken and their possible effects, this analysis assumes no changes in our financial structure.

In order to modify and manage the interest rate characteristics of our outstanding debt and to limit the effects of interest rate risks on our operations, we may utilize a variety of financial instruments, including interest rate swaps, caps and treasury locks in order to mitigate our interest rate risk on a related financial instrument. The use of these types of instruments to hedge our exposure to changes in interest rates carries additional risks, including counterparty credit risk, the enforceability of hedging contracts and the risk that unanticipated and significant changes in interest rates will cause a significant loss of basis in the contract. To limit counterparty credit risk we will seek to enter into such agreements with major financial institutions with high credit ratings. There can be no assurance that we will be able to adequately protect against the foregoing risks and will ultimately realize an

Table of Contents

economic benefit that exceeds the related amounts incurred in connection with engaging in such hedging activities. We do not enter into such contracts for speculative or trading purposes.

Equity Price Risk

We have exposure to equity price market risk because of our equity investments in certain publicly-traded companies and privately-held entities. We classify investments in publicly-traded companies as “available for sale” and, consequently, record them on our condensed consolidated balance sheets at fair-value, with unrealized gains or losses reported as a component of accumulated other comprehensive income or loss. Investments in privately-held entities are generally accounted for under the cost method because we do not influence any of the operating or financial policies of the entities in which we invest. For all investments, we recognize other-than-temporary declines in value against earnings in the same period during which the decline in value was deemed to have occurred. There is no assurance that future declines in value will not have a material adverse impact on our future results of operations. A 10% decrease in the fair-value of our equity investments as of September 30, 2015, would equal approximately \$8.1 million.

Foreign Currency Exchange Rate Risk

We have exposure to foreign currency exchange rate risk related to our subsidiary operating in the United Kingdom. The functional currency of our foreign subsidiary is GBP. Gains or losses resulting from the translation of our foreign subsidiary’s balance sheet and statement of income are included in other comprehensive income. Gains or losses will be reflected in our statements of income when there is a sale of our investment in these operations or upon a complete or substantially complete liquidation of the investment. For the three months ended September 30, 2015 and 2014, total revenues from properties outside the United States were \$4.5 million and \$6.5 million, respectively, which represented 2.6% and 3.8% of the Company's total revenues during the respective periods. For the nine months ended September 30, 2015 and 2014, total revenues from properties outside the United States were \$13.1 million and \$16.1 million, respectively, which represented 2.6% and 3.2% of our total revenues for the respective periods. Our net investment in properties outside the United States was \$211.3 million and \$200.2 million as of September 30, 2015 and December 31, 2014, respectively. On August 2, 2012, we converted a portion of the outstanding borrowings of our Term Loan due 2017 into GBP, which we designated as a net investment hedge to mitigate our risk to fluctuations in foreign currency exchange rates. As a result, our unhedged net investment in properties outside the United States was \$59.8 million as of September 30, 2015.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Controls and Procedures (BioMed Realty Trust, Inc.)

BioMed Realty Trust, Inc. maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to its management, including BioMed Realty Trust, Inc.'s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Also, BioMed Realty Trust, Inc. has investments in unconsolidated entities. As BioMed Realty Trust, Inc. manages these entities, its disclosure controls and procedures with respect to such entities are essentially consistent with those it maintains with respect to its consolidated entities.

As required by Rule 13a-15(b) under the Exchange Act, BioMed Realty Trust, Inc. carried out an evaluation, under the supervision and with the participation of its management, including BioMed Realty Trust, Inc.'s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BioMed Realty Trust, Inc.'s disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, BioMed Realty Trust, Inc.'s Chief Executive Officer and Chief Financial Officer concluded that BioMed Realty Trust, Inc.'s disclosure controls and procedures were effective at the reasonable assurance level.

There has been no change in BioMed Realty Trust, Inc.'s internal control over financial reporting during the quarter ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, BioMed Realty Trust, Inc.'s internal control over financial reporting.

Controls and Procedures (BioMed Realty, L.P.)

BioMed Realty, L.P. maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to its management, including BioMed Realty Trust, Inc.'s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Also, BioMed Realty, L.P. has investments in unconsolidated entities. As BioMed Realty, L.P. manages these entities, its disclosure controls and procedures with respect to such entities are essentially consistent with those it maintains with respect to its consolidated entities.

As required by 13a-15(b) under the Exchange Act, BioMed Realty, L.P. carried out an evaluation, under the supervision and with the participation of its management, including BioMed Realty Trust, Inc.'s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BioMed Realty, L.P.'s disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, BioMed Realty Trust, Inc.'s Chief Executive Officer and Chief Financial Officer concluded that BioMed Realty, L.P.'s disclosure controls and procedures were effective at the reasonable assurance level.

There has been no change in BioMed Realty, L.P.'s internal control over financial reporting during the quarter ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, BioMed Realty, L.P.'s internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Although we are involved in legal proceedings arising in the ordinary course of business, we are not currently a party to any legal proceedings nor is any legal proceeding threatened against us that we believe would have a material adverse effect on our financial position, results of operations or liquidity.

Following the announcement of the Merger Agreement, three purported class actions related to the proposed Mergers, Noon v. BioMed Realty Trust, Inc., et al., No. 24-C-15-005174, Lipovich v. Gold, et al., No. 24-C-15-005173 and Schwartz v. BioMed Realty Trust, Inc., et al., No. 24-C-15-005477, were filed in the Circuit Court of Maryland for Baltimore City, against us, Parent, Merger Sub I, Merger Sub II, the Sponsor, and the members of our board of directors, alleging, among other things, that our directors breached their fiduciary duties in connection with the Merger Agreement (including, but not limited to, various alleged breaches of duties of good faith, loyalty, due care and candor). The Lipovich complaint also names The Blackstone Group L.P. as a defendant. The lawsuits allege that our directors failed to take appropriate steps to maximize stockholder value, and claim that the Merger Agreement contains several deal protection provisions that are unnecessarily preclusive. The lawsuits further allege that we, Parent, Merger Sub I, Merger Sub II, the Sponsor, and, in the case of the Lipovich complaint, The Blackstone Group L.P., aided and abetted the purported breaches of fiduciary duties. The lawsuits seek a variety of equitable and injunctive relief, including enjoining defendants from completing the proposed Mergers, rescission of any consummated transaction, attorneys' fees and expenses, and, in the case of the Noon complaint, unspecified damages. We believe the lawsuits are without merit and intend to defend vigorously against them.

ITEM 1A. RISK FACTORS

Our annual report on Form 10-K for the year ended December 31, 2014 includes detailed discussions of our risk factors under the heading "Part I, Item 1A. Risk Factors." Set forth below are certain changes from the risk factors previously disclosed in our annual report on Form 10-K, which we are including in this quarterly report on Form 10-Q as a result of our entering into the Merger Agreement on October 7, 2015, as further described above. You should carefully consider the risk factors discussed in our annual report on Form 10-K, as well as the other information in this report, which could materially harm our business, financial condition, results of operations, growth prospects or the value of our securities.

Risks Related to the Mergers

There may be unexpected delays in the completion of the Mergers, or the Mergers may not be completed at all. The Mergers are currently expected to close during the first quarter of 2016, assuming that all of the conditions in the Merger Agreement are satisfied or waived. The Merger Agreement provides that either we or Parent may terminate the Merger Agreement if the Mergers have not occurred by April 7, 2016. Certain events may delay the completion of the Mergers or result in a termination of the Merger Agreement. Some of these events are outside the control of either party. In particular, completion of the Company Merger requires the affirmative vote of a majority of our outstanding common stock as of the record date for the special meeting of stockholders. If the required vote is not obtained at a special meeting (including any adjournment or postponement thereof) at which the Company Merger has been voted upon, either we or Parent may terminate the Merger Agreement. We may incur significant additional costs in connection with any delay in completing the Mergers or termination of the Merger Agreement, in addition to significant transaction costs, including legal, financial advisory, accounting, and other costs we have already incurred. We can neither assure you that the conditions to the completion of the Mergers will be satisfied or waived or that any adverse change, effect, event, circumstance, occurrence or state of facts that could give rise to the termination of the Merger Agreement will not occur, and we cannot provide any assurances as to whether or when the Mergers will be completed.

In addition, under the terms of the Merger Agreement, we may not declare or pay any future dividends (other than the regular quarterly dividend of \$0.26 per share for the quarter ended September 30, 2015 which has already been declared on September 15, 2015 and paid on October 15, 2015 to stockholders of record at the close of business on September 30, 2015) to the holders of our common stock during the term of the Merger Agreement without the prior

written consent of Parent, subject to certain exceptions. Depending on when the Mergers are consummated, these restrictions may prevent holders of our common stock from receiving dividends that they might otherwise have received.

Failure to complete the Mergers in a timely manner or at all could negatively affect our stock price and future business and financial results.

Table of Contents

There is no assurance that the Mergers will occur or that the conditions to the Mergers will be satisfied in a timely manner or at all. Also, there is no assurance that an event, change, or other circumstance that could give rise to the termination of the Merger Agreement will not occur. Delays in completing the Mergers or the failure to complete the Mergers at all could negatively affect our future business and financial results, and, in that event, the market price of our common stock may decline significantly, particularly to the extent that the current market price reflects a market assumption that the Mergers will be completed. If the Mergers are not completed for any reason, we will not achieve the expected benefits thereof and will be subject to several risks, including the diversion of management focus and resources from operational matters and other strategic opportunities while working to implement the Mergers, any of which could materially adversely affect our business, financial condition, results of operations and the value of our securities.

The pendency of the Mergers could adversely affect our business and operations.

In connection with the pending Mergers, some of our current or prospective tenants, lenders, joint venture partners or vendors may delay or defer decisions, which could negatively impact our revenues, earnings, cash flows and expenses, regardless of whether the Mergers are completed. In addition, under the Merger Agreement, we are subject to certain restrictions on the conduct of our business prior to completing the Mergers. These restrictions may prevent us from pursuing certain strategic transactions, undertaking certain capital projects, undertaking certain financing transactions and otherwise pursuing other actions that are not in the ordinary course of business, even if such actions could prove beneficial and may cause us to forego certain opportunities we might otherwise pursue absent the Merger Agreement. Additionally, the pendency of the Mergers may make it more difficult for us to effectively recruit, retain and incentivize key personnel and may cause distractions from our strategy and day-to-day operations for our current employees and management.

An adverse judgment in a lawsuit challenging the Mergers may prevent the Mergers from becoming effective or from becoming effective within the expected timeframe.

We, Parent, Merger Sub I, Merger Sub II, the Sponsor, and the members of our board of directors have been named as defendants in two purported class action lawsuits (with The Blackstone Group L.P. named as a defendant in one of these lawsuits) challenging the Mergers and seeking, among other things, to enjoin the completion of the Mergers. Our stockholders may file additional lawsuits challenging the Mergers or the other transactions contemplated by the Merger Agreement, which may name us and/or our board of directors as defendants. We cannot assure you as to the outcome of such lawsuits, including the amount of costs associated with defending these claims or any other liabilities that may be incurred in connection with the litigation of these claims. If plaintiffs are successful in obtaining an injunction prohibiting the parties from completing the Mergers on the agreed-upon terms, such an injunction may delay the completion of the Mergers in the expected timeframe, or may prevent the Mergers from being completed altogether. Whether or not any plaintiff's claim is successful, this type of litigation may result in significant costs and divert management's attention and resources, which could adversely affect the operation of our business.

Counterparties to certain of our agreements may have consent rights in connection with the Mergers.

We are party to certain agreements that give the counterparties to such agreements certain rights, including consent rights, in connection with "change in control" transactions or otherwise. Under certain of these agreements, the Mergers may constitute a "change in control" or otherwise give rise to consent rights and, therefore, the counterparties may assert their rights in connection with the Mergers, including in the case of indebtedness, acceleration of amounts due. Any such counterparty may request modifications of its agreements as a condition to granting a waiver or consent under those agreements, and there can be no assurance that such counterparties will not exercise their rights under the agreements, including termination rights where available. In addition, the failure to obtain consent under one agreement may be a default under other agreements and, thereby, trigger rights of the counterparties to such other agreements, including termination rights where available.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities and Use of Proceeds (BioMed Realty Trust, Inc.)

None.

Unregistered Sales of Equity Securities and Use of Proceeds (BioMed Realty L.P.)

During the three months ended September 30, 2015, our Parent Company issued 8,800 shares of its common stock (excluding the forfeiture of 48,987 shares of common stock over the same period) in connection with restricted stock awards under its incentive award plan for no cash consideration. For each share of common stock issued by our Parent Company in connection with such an award, the operating partnership issued a restricted operating partnership unit to our Parent Company, in reliance on the exemption

Table of Contents

from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended. During the three months ended September 30, 2015, the operating partnership issued an aggregate of 8,800 restricted operating partnership units to our Parent Company, as required by the operating partnership's partnership agreement (excluding the forfeiture of 48,987 shares of common stock over the same period).

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

Table of Contents

ITEM 6. EXHIBITS

| Exhibit Number | Description of Exhibit |
|----------------|---|
| 31.1 | Certifications of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2 | Certifications of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1 | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 2.1 | Agreement and Plan of Merger, dated as of October 7, 2015, by and among BioMed Realty Trust, Inc., BRE Edison Holdings L.P., BRE Edison L.P., BRE Edison Acquisition L.P. and BioMed Realty, L.P. (1) |
| 3.1 | Articles of Amendment of BioMed Realty Trust, Inc. (2) |
| 3.2 | Fourth Amended and Restated Bylaws of BioMed Realty Trust, Inc. (1) |
| 10.1 | Amendment Number 1 to BioMed Realty Trust, Inc. Severance Plan, dated August 26, 2015. |
| 101.INS | XBRL Instance Document. |
| 101.SCH | XBRL Taxonomy Extension Schema Document. |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. |

(1) Incorporated by reference to BioMed Realty Trust, Inc.'s and BioMed Realty, L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 8, 2015.

(2) Incorporated by reference to BioMed Realty Trust, Inc.'s and BioMed Realty, L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 28, 2015.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized.

BIOMED REALTY TRUST, INC.

BIOMED REALTY, L.P.

By: BioMed Realty Trust, Inc.

Its general partner

/s/ ALAN D. GOLD

Alan D. Gold

Chairman of the Board, President and
Chief Executive Officer

(Principal Executive Officer)

/s/ ALAN D. GOLD

Alan D. Gold

Chairman of the Board, President and
Chief Executive Officer

(Principal Executive Officer)

/s/ GREG N. LUBUSHKIN

Greg N. Lubushkin

Chief Financial Officer

(Principal Financial Officer)

/s/ GREG N. LUBUSHKIN

Greg N. Lubushkin

Chief Financial Officer

(Principal Financial Officer)

Dated: November 5, 2015

Dated: November 5, 2015